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ABSTRACT 
Atrial fibrillation is the most common type of irregular heartbeat. It is associated 
with substantial health risks, limited treatment success, and high relapse rates, and this 
chronic condition is difficult to diagnose due to transient symptoms or absence of such. 
Atrial fibrillation has important public health implications as it adversely affects one to two 
persons per hundred in psychological, social, and economic terms. 
The objective of this research was to quantitatively describe the patient’s journey 
towards the diagnosis of atrial fibrillation within an episode of illness framework. Electronic 
medical records were accessed through the DELPHI database. The patient’s lived 
experience was analyzed with descriptive statistics in terms of the number of physician 
visits, episode length, medications prescribed, diagnostic investigations ordered, and 
referrals made. The observed findings were compared to a control group of patients with 
other chronic conditions. The differences between the two groups were statistically 
significant, with an overall large effect size. 
The emerging knowledge of a patient’s journey may identify patients’ unmet needs 
and inform future public policy development in the diagnosis and management of atrial 
fibrillation. 
 
 
 
 
KEYWORDS: Atrial Fibrillation, Episode of Illness, Primary Care, Electronic Medical Records 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 
First and foremost, I would like to thank my research supervisors, Dr. Mark 
Speechley, Professor, the University of Western Ontario, and Dr. Lorne Gula, MD, 
Professor, the University of Western Ontario, for their continued support, professional 
integrity, and open-mindedness. 
 I gratefully acknowledge Dr. Amanda Terry, Assistant Professor, the University 
of Western Ontario, for her advice and knowledge sharing about electronic medical 
records, generally, and the DELPHI Database, specifically. It helped to develop my own 
way of thinking around the topic. 
I am much indebted to Dr. Heather Maddocks, Senior Data Analyst, Centre for 
Studies in Family Medicine, Schulich School of Medicine & Dentistry, the University of 
Western Ontario, for her crucial input into data analysis and insightful comments 
throughout the process.  
Many thanks go Dr. Anthony Tang, MD, CANet’s Scientific Director & CEO 
 for his generosity in providing necessary funding. 
I am very much grateful to Dr. Mary Runte, Associate Professor, University of 
Lethbridge, for her kindness in including my thesis project into her large-scale research. 
A special “thank you” is to my family for their unconditional love, inseparable 
support and divine patience.  
 
 
 
 
 
 
 
 
 
 
iv 
 
TABLE OF CONTENTS 
 
ABSTRACT .................................................................................................................................................. ii 
ACKNOWLEDGEMENTS ......................................................................................................................... iii 
TABLE OF CONTENTS ............................................................................................................................. iv 
LIST OF TABLES ...................................................................................................................................... vii 
LIST OF FIGURES ................................................................................................................................... viii 
LIST OF APPENDICES .............................................................................................................................. ix 
LIST OF ABREVIATIONS ......................................................................................................................... x 
 
CHAPTER ONE – INTRODUCTION 
1.1 Thesis Overview ................................................................................................................................. 1  
 
CHAPTER TWO – LITERATURE REVIEW ............................................................................................. 3 
2.1 Overview of Atrial Fibrillation ........................................................................................................... 3 
2.2 The Concept of an Outpatient Medical Encounter .............................................................................. 8 
2.3 The Concept of an Episode of Illness ................................................................................................. 8 
2.4 Symptomatology in Atrial Fibrillation and Associated Challenges .................................................. 12 
2.5 Atrial Fibrillation-Specific Symptoms .............................................................................................. 15 
2.6 The Concept of Symptom Clusters ................................................................................................... 17 
2.7 Atrial Fibrillation-Specific Clusters .................................................................................................. 17 
2.8 Clinical Assessment of Atrial Fibrillation ........................................................................................ 19 
2.9 Methods for Detecting Atrial Fibrillation ......................................................................................... 20 
2.10 Drug Therapies Prior to Diagnosis of Atrial Fibrillation ................................................................ 22 
2.11 Indications for Referral of Patients with Atrial Fibrillation ............................................................ 24 
2.12 Patient-Centered Care and Lived Experience of Atrial Fibrillation ................................................ 26 
 
CHAPTER THREE – METHODS 
3.1 Objectives ......................................................................................................................................... 29 
3.2 The Deliver Primary Health Care Information (DELPHI) Database as a Source of Data ................ 30 
3.3 The International Classification of Primary Care (ICPC) ................................................................. 31 
3.4 Episodes of Atrial Fibrillation Illness Defined Using ICPC-Coded Data ......................................... 34 
3.5 Look-Back Period and Left-Censored Data ...................................................................................... 34 
v 
 
3.6 Definition of Independent Variables ................................................................................................. 35 
3.6.1 Study Group ............................................................................................................................... 35 
3.6.2 Control Group ............................................................................................................................ 35 
3.7 Definition of Dependent Variables ................................................................................................... 36 
3.7.1 Number of Physician Visits ....................................................................................................... 37 
3.7.2 Episode Length .......................................................................................................................... 37 
3.7.3 Medication ................................................................................................................................. 37 
3.7.4 Diagnostic Investigation ............................................................................................................ 38 
3.7.5 Rationale for Lag Period in Definition of Diagnostic Investigation .......................................... 39 
3.7.6 Referral ...................................................................................................................................... 39 
3.7 7 Rationale for Lag Period in Definition of Referral .................................................................... 40 
3.8 Data Analysis Objective One: Characteristics of an Atrial Fibrillation Episode of Illness .............. 40 
3.9 Data Analysis Objective Two: Comparison of Study Group and Control Group. ............................ 40 
3.9.1 An Independent-Samples T-Test ............................................................................................... 40 
3.9.2 Underlying Assumptions for an Independent-Samples T-Test .................................................. 41 
3.9.3 Effect Size Statistics Data .......................................................................................................... 41 
3.9.4 Missing Data .............................................................................................................................. 42 
3.9.5 Outlying Points .......................................................................................................................... 42 
 
CHAPTER FOUR – RESULTS 
4.1 Sample Description ........................................................................................................................... 43 
4.2 Objective One: Characteristics of an Atrial Fibrillation Episode of Illness ...................................... 50 
4.3 Objective Two:Comparison of Study Group and Control Group. An Independent-Samples T-Test 57 
4.4 Objective Two: Magnitude of Effect. Effect Size Statistics ............................................................. 65 
 
CHAPTER FIVE - DISCUSSION AND CONCLUSION 
5.1 Strengths of Research ....................................................................................................................... 71 
5.2 Limitations of Research .................................................................................................................... 72 
5.3 Objective One: Characteristics of an Atrial Fibrillation Episode of Illness ...................................... 73 
5.3.1 Number of Physician Visits ....................................................................................................... 73 
5.3.2 Episode Length .......................................................................................................................... 75 
5.3.3 Medication ................................................................................................................................. 76 
5.3.4 Investigation ............................................................................................................................... 77 
vi 
 
5.4 Objective Two: Effect Size in Study Group and Comparison Group ............................................... 77 
5.5 Generalizability of Results ................................................................................................................ 78 
5.5.1 Representativeness of DELPHI Population in Comparison to General Practice Populaton ...... 78 
5.5.2 Compatibility of the DELPHI Database with Other Electronic Medical Record Databases ..... 80 
        5.5.3 Comparison of ICPC-Coded DELPHI Population and 2016 Canadian Census Population  ...... 81 
5.6 Policy Implications ........................................................................................................................... 82 
5.7 Future Research ................................................................................................................................ 83 
5.8 Conclusion ........................................................................................................................................ 84 
BIBLIOGRAPHY ....................................................................................................................................... 85 
APPENDICES .......................................................................................................................................... 101 
CURRICULUM VITAE ........................................................................................................................... 124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
LIST OF TABLES 
 
Chapter Table Description Page 
 
2 
 
1 
 
Indications for Referral of Patients with Suspected Atrial 
Fibrillation 
 
 
23 
4 2 Description of Sample 
 
43 
4 3 Episode of Illness Characteristics 
 
50 
4 4 Group Statistics for Independent-Samples T-Test 
 
58 
4 5 Independent-Samples T-Test 
 
59 
4 6 Comparison of Standard One-Way ANOVA and Independent-
Samples T-Test (under ‘Equal Variances Assumed’) Results 
 
61 
4 7 Comparison of Robust Tests of Equality of Means and 
Independent-Samples T-Test (under ‘Equal Variances Not 
Assumed’) Results 
 
62 
4 8 Summary of Effect Size Calculations 
 
67 
 
 
 
  
viii 
 
LIST OF FIGURES 
 
Chapter Figure Description Page 
 
2 
 
1 
 
Types of Atrial Fibrillation 
 
5 
 
3 
 
2 
 
Types of Health Care Episodes 
 
9 
 
 
 
 
  
ix 
 
LIST OF APPENDICES 
 
Appendix Description Page 
 
A 
 
List of Atrial Fibrillation-Related ICPC Diagnostic Codes 
 
 
99 
B List of Chronic ICPC Diagnostic Codes 
 
100 
C List of Musculoskeletal ICPC Diagnostic Codes 
 
102 
D List of Psychosocial ICPC Diagnostic Codes 
 
104 
E Measures of Effect Size 
 
107 
F Manual Calculation of Effect Size: Eta Squared 
 
110 
G Semi-Manual Calculation of Effect Size: Eta Squared 
 
111 
H Summary Table of Eta Squared Values 
 
113 
I Calculation of Cohen’s d 
 
115 
J Calculation of Hedge’s g 
 
117 
K Representativeness of DELPHI Population 
 
119 
L Age and Sex Distribution in the ICPC-Coded DELPHI Population and 
the 2016 Canadian Census Population 
121 
 
x 
 
LIST OF ABBREVIATIONS 
 
Abbreviation Meaning 
 
AF 
 
Atrial Fibrillation 
 
APA the American Psychological Association 
 
BPMs Blood Pressure Monitors 
 
CI Confidence Interval 
 
COPD Chronic Obstructive Pulmonary Disease 
 
CT Scan Computerized Tomography Scan 
 
CVD Cardiovascular Disease 
 
CPCSSN the Canadian Primary Care Sentinel Surveillance Network 
 
the DELPHI Project the Deliver Primary Healthcare Information Project 
 
ECG 
 
ED 
Electrocardiogram 
 
Emergency Department 
 
EMRs Electronic Medical Records 
 
ICPC 
 
MACE 
 
MI 
 
International Classification of Primary Care 
 
Major Adverse Cardiac Event 
 
Myocardial Infarction 
NOS Not Otherwise Specified 
 
PHC Primary Health Care 
 
PCC Patient-Centered Care 
 
RFE Reason for Encounter 
 
SD Standard Deviation 
 
 
1 
 
CHAPTER ONE – INTRODUCTION 
 
1.1 Thesis Overview  
The overall objective of this thesis was to quantitatively describe the lived 
experience of patients diagnosed in primary care with the most common sustained 
cardiac arrhythmia called Atrial Fibrillation (AF).   
It is important to capture the disease experience from the patients’ in addition to  
health care providers’ perspective for several reasons.  First, AF is accompanied by 
substantial health risks and patients deal with uncertainty around the diagnosis of AF. .  
This ongoing  uncertainty can significantly affect patients’ quality of life1. Furthermore, 
despite the patient’s high compliance with the treatment protocol, the achieved success 
is limited and relapse rates are high. Second, AF has public health implications because 
it affects one to two persons per hundred not only physically but also in psychological, 
social and economic terms.  Third, due to ambiguous and transient symptomatology or 
absence of such, AF is difficult to diagnose, thus leading to a protracted assessment 
period. This adds to emotional distress and significantly disrupts daily living of AF 
patients and their families as well as delays the start of evidence-based disease 
management.   
Health service researchers have devised a concept called the episode of care that 
is suitable for studying the experience of people with a health condition.  While there 
exist different definitions, the one operationally used in this thesis is the time-period 
from the first ICPC-coded  outpatient encounter as a starting point to the date of 
diagnosis as an end-point.  This definition was applied using a sophisticated ICPC-coded 
portion of the DELPHI database (Deliver Primary Healthcare Information). As a result, 
we identified69 primary care patients that were seen by 23 physicians in 10  practices 
over a ten-year period (2006-2015). The ten-year prevalence of AF in the DELPHI 
database (including the ICPC-coded portion) is 3.1% in the patient population of 48,387 
individuals (Appendix K). Approximately 10% of the DELPHI patient population was 
coded using ICPC and the ten-year prevalence of AF among the ICPC-coded population 
of 4,838 persons is 1.98%, i. e.., with 69 identified cases. In other words, 23 family 
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doctors in 10 practices diagnosed AF in 69 out of 4,838 ICPC-coded patients over a span 
of 10 years. 
The following variables pertaining to the length of time between the first 
outpatient medical encounter and the final diagnosis within an episode of illness were 
studied: 1) the number of physician visits; 2) the episode length; 3) the number and type 
of medications prescribed; 4) the number and type of diagnostic investigations ordered; 
and 5) the number and type of referrals made.  
The thesis is organized as follows.  Chapter 2 contains a review of the literature 
on AF as well as the concepts of an outpatient medical encounter and an episode of care.  
It is followed by the description of the Methods used in Chapter 3.  Chapter 4 contains 
the results of the analyses whereas Chapter 5 is devoted to Discussion and Conclusion. 
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CHAPTER TWO – LITERATURE REVIEW 
This chapter will present the review of the published literature on the 
epidemiology of AF, the concepts of outpatient medical encounters, episodes of illness, 
symptomatology and methods for detecting AF as well as touch upon early drug therapies 
prior to the confirmatory diagnosis of AF.  
 
2.1 Overview of AF 
Being the most common sustained cardiac arrhythmia, AF affects 1-2% of the 
general population.2, 3  Aging is associated with an increased risk of developing AF, 
potentially through age-related isolation and loss of atrial myocardium.4 Thus, at the age 
of 40-50, the prevalence of AF is less than 0.5% whereas between 65 and 69 years of 
age, it is 2%5 and at 80 years, it increases up to 8-15%.3, 2, 6, 7, 8 Within the next 50 years, 
as the population ages, the prevalence of AF is expected to double.4 Men are usually 
more affected than women. AF, especially of an early onset, has a genetic 
predisposition.9 
The classical risk factors for developing AF include cardiac and non-cardiac 
conditions such as ischaemic cardiomyopathy, valvular disease, hypertension, thyroid 
disease and diabetes10. Parental AF as a risk factor for AF in offspring9 is also present. 
The findings of the study conducted by Fox et al.9 demonstrated that a familial 
component predicted an increased risk of offspring AF, after having adjusted for other 
standard AF risks with genetic components (i.e., diabetes, hypertension, and myocardial 
infarction). 
In some patients, AF (also known as lone AF) has an idiopathic aetiology, with 
no underlying pathology. In recent years, however, clinicians and researchers started 
talking about “not-so-lone atrial fibrillation”11  and evaluated “new risk factors”11 as 
playing a role in the genesis of AF. Among the “new risk factors”11 (as juxtaposed to the 
classical risk factors) are overweight and obesity, sleep apnea, sedentary life style,  its 
counterpart – excessive sports practice, inflammation, latent hypertension, abuse of 
alcohol and other substances.  
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AF is an independent risk factor for stroke: in its presence, the risk of stroke is 5 
times higher and increases with age.5 Ischaemic strokes in combination with AF lead 
twice as often to fatalities, and survivors are more disabled by their stroke and more 
likely to experience a recurrence than patients with other stroke causes.4, 12  
AF is associated with increased rates of heart failure and hospitalizations.4 
Cognitive dysfunction,13 impaired quality of life14 and reduced exercise capacity15 are 
other negative consequences that AF patients experience on a daily basis. 
Approximately 67% of all emergency department visits with a primary diagnosis of AF 
get hospitalized to acute inpatient units.16, 17  
A retrospective cohort study of emergency department patients with a primary 
diagnosis of AF18 over an eight-year period (2002-2010) in the province of Ontario 
found that the frequency of AF as well as proxy measures for its severity (CHADS2 
score and triage category) increased. There was a relative increase of 29% in the number 
of AF-related emergency department (ED) visits in 8 years. This increase included 
approximately 20% of patients who were readmitted to ED for AF18. Over time, 
however, the admission rates decreased, accounting for 0.5% of all ED visits. The 
authors attributed the observed increase partly (about 15 % of the increase) to aging of 
the population18. Another possible explanation suggested by Tu et al.19 - as they 
analyzed mortality data from Statistic Canada's Canadian Mortality Database for the 
period of 1994-2004 – is longer survival of patients with congestive heart failure, 
myocardial infarction, and stroke. AF is also associated with a number of medical 
conditions that are risk markers rather than solely causative agents.4 Among the 
comorbidities are both various cardiomyopathies20, 21, 22 and other medical conditions. 
Based on their prevalence in the general population, it is worth mentioning the following 
disorders : diabetes mellitus4 (20% of AF population); chronic obstructive pulmonary 
disease (COPD) (10-15% of AF population)4; obesity (25% of AF population)21; 
hypertension, sleep apnea and chronic renal disease (10-15% of AF patients).4 Although 
relatively uncommon in the AF population,20, 21 thyroid dysfunction alone can cause AF 
and AF-related complications. 
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Management of AF patients is dependent on the type of AF which, in turn, is 
based on clinical presentation and duration of the arrhythmia.4 Specifically, anti-
thrombotic treatment protocol is dependent on the definition of the valvular (rheumatic) 
versus non-valvular (hypertensive) origin of AF23. There are five main types of AF: 
paroxysmal, persistent, long-standing persistent, permanent and silent AF (Figure 1).4  
A patient presenting with AF for the first time is deemed to have first diagnosed 
AF. Paroxysmal AF terminates by itself usually within 48 hours of onset. Although AF 
paroxysms can last up to 7 days, the 48-hour time window is clinically relevant for the 
management of AF.  
After 48 hours, sinus rhythm is not likely to spontaneously return and 
anticoagulation therapy must be implemented. First of all, to improve cardiac 
performance and to alleviate symptoms24, there may be a need for pharmacological (for 
recent-onset AF) or electrical cardioversion (for prolonged AF). Unfortunately, 
cardioversion is an inherent risk factor for thromboembolism25. The risk associated with 
cardioversion can be minimized from 5-7%26 to less than 1%27 with prophylactic 
anticoagulation therapy. Anticoagulation is highly recommended before and after 
cardioversion. The traditional anticoagulant has been warfarin24. Recently, after having 
demonstrated their non-inferiority to warfarin in clinical trials28, the direct oral 
anticoagulants have also been approved24.  
When an AF episode lasts longer than 7 days or cardioversion is used to 
terminate it, the diagnosis is persistent AF.  
Whether rhythm control management is desired or not, there distinguish two 
more types of AF: long-standing persistent AF and permanent AF. Long-standing 
persistent AF lasts longer than one year and a rhythm control protocol is adopted. With 
permanent AF, its existence is recognized by the patient and the physician and there is 
no pursuit of rhythm control interventions. 
Finally, silent AF is asymptomatic in nature and is often diagnosed by an 
opportunistic electrocardiogram (ECG). Silent AF can be of any temporal form of AF.  
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Because the objective of this thesis was to quantitatively describe a patient’s 
journey to the diagnosis of AF and based on the available data, the emphasis was on first 
diagnosed episodes of AF, without further distinguishing its subtypes. 
 
 
Figure 1: Types of Atrial Fibrillation1 
  
 
  
                                                          
1 Source: Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial 
fibrillation. Eur Heart J. 2010;31(19):2369-2429. doi:10.1093/eurheartj/ehq278 
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An irregular pulse can be indicative of the underlying AF in individuals 
presenting with chest pain, palpitations, breathlessness and dizziness.29, 30, 31, 32 At the 
same time, AF can present with a variety of non-specific symptoms that may differ not 
only between patients but in the same individuals over time.15 At the opposite end of the 
spectrum are asymptomatic cases and this proportion can be as high as 15% -30% of the 
AF population15, 33, 34, 35. Indeed, many patients in a primary care setting remain 
asymptomatic at the time of their first encounter with their family physicians.36 
It is key to identify, assess and diagnose patients with AF, especially the 
asymptomatic cohort, so that they can receive prompt treatment.36 The recommended 
strategy for early detection and management of AF is to perform opportunistic (≥65 
years), routine (known risk factors or cardiovascular disease) or triggered (suspicious 
symptoms or palpitations)  screening in general practice 29,37. Once patients are 
diagnosed with an underlying cardiovascular disease, hypertension and diabetes, it is 
prudent to assess them for the presence of AF. For pragmatic purposes,  screening in 
primary care is easy to conduct since such patients regularly see their family physicians 
for routine check-ups.36 In order not to miss an opportunity of diagnosing the pre-
existing AF and giving timely antithrombotic treatment to patients at risk,36 it is good 
practice to check blood pressure and pulse.  Antiarrhythmic therapy is also appropriate 
for specific case scenarios: for symptomatic, young, active patients, and in recent-onset 
AF)38. 
General management of AF includes the following five strategies:4 1) anti-
thrombotic treatment; 2) relief of symptoms; 3) ventricular rate control; 4) management 
of cardiovascular comorbidities; and 5) maintenance of sinus rhythm. However, the 
recent research39 has demonstrated no clinical value of rhythm disturbance correction. 
Strict rate control therapy has not been proven advantageous, either.4 Unfortunately, 
‘upstream’ drug therapies  and life style modification strategies (exercise, diet, fish oil) 
aiming at delaying or preventing myocardial remodeling, have also achieved modest 
success.40 A modest treatment effect and high rates of reoccurence41 are accompanied by 
other negative consequences such as psychological, social, economic and employment-
related. 
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2.2 The Concept of an Outpatient Medical Encounter  
An encounter (visit) in a primary care setting starts with a patient presenting with 
one or more reasons for the encounter, either in the form of a symptom or complaint, a 
diagnosis or a request for an intervention, such as filling prescriptions, advice or a 
referral to a specialist.42 The family physician establishes the most likely diagnosis and 
performs one or more interventions. Sometimes, on the basis of a most probable 
diagnosis, the doctor monitors the patient by so-called “watchful waiting”43, 44 This 
widely accepted representation of the doctor–patient encounter is considered to be an 
international standard approach. 45, 44 
From the health care system standpoint and for billing purposes, a patient-doctor 
encounter constitutes a face-to-face documented visit during which the provider (doctor) 
exercises an independent judgment while providing services to the client (patient). The 
encounter criteria are extended to such services as X-rays, prescription refills, 
vaccinations and laboratory tests. In order to be classified as an encounter, services 
rendered must be billed.  
In this research, an outpatient medical encounter is defined as an in-office 
physical contact during which the family physician provides any medical service to the 
patient. Each date of service in a primary care setting constitutes a separate encounter, 
i.e., one “billable” medical encounter per patient per day. Although there exist different 
provider types, in the DELPHI database the provider is a general practitioner who is 
primarily responsible for assessing the patient and documenting the services rendered in 
the patient’s electronic medical record (EMR). The patient (user, client) is defined as an 
individual who had at least one encounter. Each patient is counted only once regardless 
of the number of services received.   
 
2.3 The Concept of an Episode of Illness 
The literature recognizes different types of episode concepts46, 47  .  There exist 
four distinct perspectives on the definition of a health care episode 48: 1) an episode of 
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illness or indisposition (from the patient’s perspective); 2) an episode of disease (from 
the care provider’s standpoint); 3) an episode of care (from the payer’s or the health care 
system perspective) and 4) a health maintenance episode (from the societal perspective). 
Each episode, regardless of its type, has a defined starting and end-point and the 
end-point is the same for all types – disease resolution or patient’s death. It is accepted 
in the literature, however, that some diseases (for instance, chronic conditions) may be 
open-ended, with no discrete starting and end-points.46 In such a case, based on its 
technologic feasibility, the treatment is shifted from “cure” or “resolution” to 
“maintenance” or “palliation”. 
 From a patient’s perspective, an episode of illness or indisposition entails a 
continuous time-period that the patient is suffering from a medical condition. The patient 
may experiences a continuous spell of symptoms that are perceived as ill-health46. 
Symptoms are experienced and reported by the patient (subjective) whereas signs are 
observed by the health care provider (objective). 
From a care provider’s perspective, an episode of disease constitutes a time-
period that starts at the disease diagnosis and ends at its resolution or until the patient’s 
death49.  
From a payer-centric standpoint, an episode of care is a set of associated 
healthcare services to the diagnosis and treatment of a complaint. The broad definition 
of an episode of care refers to a health problem from its first to the last encounter with a 
family physician49.  
Health maintenance episodes describe encounters with the health care system 
that do not involve an illness or a disease46: health promotion, cosmetic procedures, 
employment-related physical examinations, etc.  
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Figure 2: Types of Heath Care Episodes 
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The episode of care concept is easily defined for acute-onset events such as hip 
fracture, but more challenging to use to capture the patient’s experience of AF, 
particularly in the stressful time before the definitive diagnosis.  This is because the 
specific encounter that eventually led to the diagnosis may have been for one or more of 
the many non-specific symptoms of AF.   
To capture the patient’s experience towards the diagnosis of AF, an episode of 
illness  is operationally defined as a time-period from the first ICPC-coded encounter as 
a starting point to the date of diagnosis as an end-point. Episode-framed patient data 
allow a more thorough evaluation of the degree to which family practitioners are 
involved in a vast majority of patient’s health care needs49. The notion of an episode of 
illness also enables to capture the patient’s lived experience.  
Relevance of a medical encounter to the diagnosis of AF will be determined 
based on reasons for encounter as reported by patients. Although symptomatology is a 
major reason for patients with AF to see their family physicians,15 other reasons for 
encounter may be in place: for instance, medication renewal, regular check up, blood 
tests, preventive immunization, etc. From the established diagnosis of AF, we will 
attempt to retrospectively cluster different encounters into an episode of illness.  
All the encounters within the patient’s electronic medical record are considered 
for inclusion into an episode of illness and apparently unrelated ones (“sprained ankle”, 
“frozen shoulder”, etc.) are excluded from the subsequent analyses.  
An episode is a meaningful unit of analysis for evaluating primary services 
utilization in treating a particular health problem. Episode-of-care analyses have been 
conducted in a wide range of studies50 assessing the efficiency and quality of care; 
evaluating charges in different clinical settings; exploring physician referral patterns and 
patient resource utilization. Studies of the effect of cost-sharing on patient behavior50 also 
used the concept of an episode of care as a unit of analysis. 
The framework of an episode of care has the potential of better reflecting general 
practice care, overall46, and a patient’s journey, in particular.  It allows us to maintain 
the continuity of care dimension51 which is not the case with, for instance, a commonly 
used visit-per-visit framework of analysis. Family physicians provide not only personal, 
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but also factual continuity of care. As far as the personal component is concerned, the 
patient presents to the doctor with any health-related problem at any stage of 
development49. The factual continuity of care, on the other hand, is much broader in its 
scope: the physician keeps the medical health records of the patients up to date in a 
structured manner, over a period of time, while accounting for professional field and 
societal changes49. 
 
2.4 Symptomatology in Atrial Fibrillation and Associated Challenges 
For any disease, symptom report is key as it drives medical care, serves as 
motivation  for treatment adherence and serves both as a clinically relevant outcome for 
patient care and a benchmark in clinical decision-making.52 Accurate symptom reporting 
could improve symptom palliation and differential diagnosis. 
Despite the fact that AF was first recognized as early as in 1906,53 its 
symptomatology has not been thoroughly evaluated.52 Signs and symptoms ˗ generic and 
disease-specific ones - have a great variability in AF35. Some patients have no 
symptoms, and the condition is discovered incidentally.  In others, the generic symptoms 
can be clinically presented by weakness, fatigue, dizziness and exercise intolerance. The 
disease-specific symptoms include heart palpitations, chest pain, pressure or discomfort 
and shortness of breath. Until now, there has not been developed a “gold standard” in 
terms of standardized assessment of AF-related symptoms. This lack of standardization 
can have a detrimental effect on management of AF as decision-making in AF is 
primarily symptom-driven.54 Additional challenges arise due to high variability of 
symptoms not only among patients but also in individual patients at different points in 
time15. 
In the Euro Heart Survey of Atrial Fibrillation,55 69% of patients presented with 
AF-specific symptoms. Fifty-four percent  of currently asymptomatic patients had 
experienced AF symptoms in the past  .20 Holter 24-hour monitoring demonstrated that 
patients with symptomatic paroxysmal AF were 10-fold more likely to have an 
13 
 
asymptomatic versus a symptomatic recurrence.52 Overall, many patients’ experience 
consists of both symptomatic and asymptomatic episodes of AF.56, 57, 58, 59  
Although patient symptoms are extremely important in detecting and treating 
AF,52 they have no diagnostic capacity for “silent” AF. The proportion of asymptomatic 
AF patients is approximately between 15% and 30%.15, 33, 34, 35 A few studies showed 
that 65% of documented AF episodes are not associated with any symptoms in nature.60 
Notwithstanding “silent” AF, there are other reasons that make patient symptoms 
an unreliable diagnostic tool. In a study of 518 consecutive 24-hour electrocardiographic 
recordings,61 less than 10% of patients reported palpitations accurately. The researchers 
of this study also found little correlation between the type of arrhythmia and the specific 
nature of the patient’s symptoms.61 It is widely recognized in the literature that a cardiac 
pathology and symptoms do not correspond on a one-to-one, fixed basis.62 
Patients with a history of AF often report symptoms attributable to AF when in 
normal sinus rhythm.52 In other words, there are many patients with palpitations that do 
not have arrhythmias.62 The transtelephonic monitoring study by Bhandari et al.63 
demonstrated that 69% of symptomatic patients were recorded to have arrhythmia. 
Thirty-one percent  of those patients who complained of AF symptoms had normal sinus 
rhythm.63 In a later study, Gerstenfeld et al.64 confirmed that AF-specific symptoms 
could equally occur in normal sinus rhythm versus AF. Furthermore, a patient with AF 
is treated to achieve ideal rate control that minimizes arrhythmic symptoms.  
Alongside physiologic variables, such psychological variables as anxiety, stress 
and depression come into play. Symptom-wise, there is a lot of overlap between 
psychological distress and AF. Furthermore, a panic attack can not only mimic AF 
symptoms but also aggravate them. Unfortunately, no systematic evaluation of both 
physiologic and psychological variables that might affect patient-reported AF symptoms 
has been conducted to date.52   
Other cardiovascular comorbidities, such as heart failure and valve disease, in 
combination with AF produce similar symptoms.15 It is difficult to dissect AF-related 
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symptoms from the symptoms caused by co-morbidities: heart failure may be secondary 
to AF and vice versa 
In cardiology, the term “palpitations” is sometimes referred to as a “bland label” 
that requires further operationalization.65 Palpitation is defined as a sudden awareness of 
one’s heartbeat. It can be described as skipping, racing, stopping, pounding, or 
fluttering.62 By its nature, the term is vague and ambiguous65 and neither physicians nor 
patients explicate the precise meaning in which they use the term. As a result, an 
electronic medical record database is filled with “symptoms within symptoms” or 
“information within the information”62 that needs to be accounted for in the research 
process. At the stage of analysis, per se, there is an important requirement to precisely 
define a set of potential predictive variables. 
The majority of symptomatology studies were conducted on hospital-based 
cohorts or on subjects referred for AF assessment.15 Consequently, the study results can 
have limited generalizability: hospital-based cohorts may be different from population- 
and community-based cohorts.36 In hospital-based studies, the risk of selection bias is 
high. This is particularly true since many patients either present to hospital due to an 
associated comorbidity or do not go to hospital at all.  
There are major gaps in knowledge about whether there is a clinically relevant, 
mechanistic link between symptoms and the final diagnosis of AF in primary care.66, 50 
Little is known about the patient’s experience of AF in relation to functional status and 
magnitude of symptoms in general practice. Symptoms may be non-specific for AF (for 
instance, anxiety and fatigue).15 It is often the case when the patient has other 
cardiovascular comorbidities. Risk factors for AF and comorbidities can initiate similar 
symptoms. Research is complicated by the fact that AF is often accompanied by valve 
disease and heart failure – the two conditions with similar symptomatology.15  
Heart failure is common in AF patients as both diseases have major risk factors 
in common, such as diabetes mellitus, myocardial infarction, valve disease and 
hypertension.67 Furthermore, each condition can predispose to the other one: AF 
predisposes to heart failure and vice versa. The ‘safe’ conclusion would be that 
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symptoms attributable to AF are multifactorial due to their direct and indirect effects of 
the underlying arrhythmia.15 
Physicians already predict the presence of AF from different sources – albeit 
non-quantitatively and informally.68 Their decision-making is based on diagnostic 
investigations, physical examination findings and on patient’s symptoms and observed 
signs. Identifying symptom patterns can be important in predicting the diagnosis of AF 
for the selected patient populations and in defining clinical states for individual 
patients.68 
Using the database of the Transition Project, Lamberts et al.66 calculated 
posterior probabilities (in the form of an odds ratio) of the final diagnosis in general 
practice. The International Classification in Primary Care (ICPC) was used to code both 
the reason for encounter and the diagnosis. As a result of the Transition Project, a 
database with a total of 201,127 patient-years for the period of 1985-2002 was created.66  
The question of interest was whether there was a clinically relevant relationship 
between two simultaneously occurring events – a symptom and a diagnosis – in general 
practice. Out of a few conditions, the highest odds ratios of 32.5 were reported  for AF. 
These results are promising as the high value of posterior probability is indicative of the 
clinical relevance of physician observations.  
The posterior probability approach enabled the authors to determine the clinical 
relevance of general practitioners’ observations and only ‘certain’ or verified diagnoses 
were used in the calculation.66 Symptoms as predictive variables for the diagnosis 
provide evidence-based support for clinical work. With calculated posterior probabilities 
for primary care,66 it is possible to determine whether a specific symptom plays an 
important role in diagnosis while another symptom contributes little or nothing to it. 
2.5 Symptomatology  
Based on the literature review, the following symptoms related to AF were 
distinguished: 1) palpitations; 2) chest pain or discomfort; 3) shortness of breath; 4) 
reduced exercise capacity, and 5) dizziness. 
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Palpitations, or increased awareness of heartbeat irregularity: More than 50% of 
patients with AF report having palpitations or are aware of their heartbeat irregularity. 
Even though the correlation of palpitations with arrhythmia was the strongest of all other 
AF-related symptoms (palpitations occurred more frequently during AF (67%) versus 
sinus rhythm (24%))52, the value of 67% is far from definitive for the diagnosis 
establishment. 
Interestingly, but not surprisingly, the perception of arrhythmia (not its presence) 
and neuropsychiatric variables are strongly correlated. It is conceivable that a patient 
experiencing anxiety or a negative emotion is more likely to report arrhythmia when in 
normal sinus rhythm.52 Psychological distress potentially augments a patient’s 
perception of ill-health and disease symptomatology.52 
Chest pain or discomfort: Chest discomfort, pressure and pain often occur during 
AF episodes even in the absence of structural heart diseases69 such as critical valve 
disease or coronary disease.70 
Dyspnea or shortness of breath: Dyspnea is an indirect consequence of AF15 and 
can be accompanied by any type of intracardiac pressures – low, normal and elevated.70 
It is commonly accepted that elevated intracardiac pressures can initiate ventricular 
arrhythmias71. In vivo humans and in isolated hearts, acute ventricular dilatation has 
potentially arrhythmogenic effects71 
Exercise intolerance or reduced exercise capacity: As measured by New York 
Heart Association,72 over 50% of AF patients experience reduced exercise capacity. 
Reduction in exercise performance may be due to dyspnea or may be non-specific.73 The 
New York Heart Association classifies cardiac patients based on the clinical severity and 
prognosis of their conditions and distinguishes four classes of functional capacity. 
Functional capacity is an estimate of how much physical activity the patient’s heart will 
tolerate and is based entirely on subjective symptoms72 The status of cardiac functional 
capacity informs subsequent management of the patient’s activities . Similarly to 
dyspnea, patients may have reduced exercise capacity due to arrhythmia with low or 
even normal intracardiac pressures.74 Dizziness, syncope and presyncope are rarely 
reported by patients with AF.15 
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2.6 The Concept of Symptom Clusters 
Symptom clusters have long been used for diagnostic purposes in general 
medicine. Even though a medical diagnosis is ultimately dependent on diagnostic tests, 
symptoms still play a fundamental role in disease detection.75 By understanding 
symptom clusters, clinicians can develop more accurate and comprehensive diagnostic 
tools.75 
A symptom cluster consists of two or more concurrent symptoms that are related 
to each other and may or may not share common etiology. This definition requires 
further clarification:75 
1) In terms of the number of symptoms within a cluster, the presence of at least 
two symptoms serves as an antecedent for a symptom cluster. 
2)  The meaning of symptom is extended to include both signs (objective, 
observed by the clinician) and symptoms (subjective, self-reported by the patient).  
3) A symptom cluster consists of a stable group of symptoms, i.e., symptom 
patterns that are replicated across time and subjects. In case of AF, stability of symptoms 
cannot be easily achieved due to high inter-  and intra-individual variability,15 yet needs 
to be assumed for diagnostic purposes.75 
4) Each symptom cluster is relatively independent of other clusters.  
5) The relationships among symptoms within a cluster should be stronger than 
the ones across clusters. Otherwise, the symptom cluster could not identify specific 
underlying dimensions of symptoms.  
6) Etiology in the context of general medicine refers primarily to the underlying 
biological mechanism of a symptom. 
 
2.7 Atrial Fibrillation-Specific Symptom Clusters 
As a new area of cardiovascular research,76,77 symptom clustering is a group of 
two or more related symptoms  due to shared underlying mechanism, common effect on 
outcomes and covariance.78, 75 Several researchers not only identified symptom clusters 
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but also described an association between cardiovascular symptom clusters and 
outcomes of interest.76, 79, 8081 
Gaps in knowledge in regards to AF symptom clustering make it difficult for 
physicians to develop appropriately individualized, patient-centred treatment plans.78 
Therefore, additional information gained from cluster analysis can be used to tailor 
management approaches to the needs of an individual patient.  
Cardiovascular symptom clustering has already been explored in a number of 
studies77, 78, 76. Some researchers went beyond the strictly descriptive aspect of cluster 
identification and analyzed symptom clusters for their association with outcomes of 
interest. Thus, Song et al. explored possible associations between symptom clusters and 
event-free survival in 421 patients with heart failure.79  
The study by Hwang et al.80 attempted to answer the question of whether atypical 
symptom clustering predicts a higher mortality in 391 patients with first-time acute 
myocardial infarction. Finally, a few years later the same researcher explored the 
relationship between cluster dyads of risk factors and symptoms and major adverse 
cardiac events (MACE) in 522 patients with acute myocardial infarction.81 The outcome 
of interest was the incidence of 12-month MACE after the myocardial infarction81. 
Based on the association between the risk factors and symptom clusters, Hwang and 
Kim identified six cluster dyads and confirmed them to be a significant predictor of 12-
moth MACEs. The incidence of adverse cardiac events was three times higher in the 
hypertension/diabetes/atypical symptoms dyad than in the dyslipidemia/smoking/typical 
symptoms dyad. In their analyses, the researchers accounted for age, gender, and a type 
of MI diagnosis. The study results suggest that, in order to prevent MACEs via risk 
stratification, clinicians need to take into consideration both symptoms and risk factors 
at clinical presentation81. 
In application to AF, Streur and her colleagues78  identified AF-specific 
symptom clusters in 1501 adults, characterized individuals within each cluster and 
assessed cluster association with an end-point of healthcare utilization. Patients’ 
utilization of heath care services was defined as the number of emergency department 
(ED) visits, AF-related hospitalizations and cardioversions patients had within the past 
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12 months.78 The researchers identified two clusters that met the definition of a 
symptom cluster (two or more simultaneously occurring symptoms) and labelled them 
as 1) the Weary cluster (shortness of breath at rest, fatigue at rest, dizziness, and chest 
pain) and 2) the Exertional cluster (dyspnea with activity and exercise intolerance). The 
most common symptoms were exercise intolerance (42%), dyspnea with activity (40%) 
and palpitations (33%).   
Another study used participants from the SAFETY trial77, 82 and identified AF-
specific symptom clusters that differed from those in the study by Streur et al.78 In the 
order of their frequency, the clusters from the SAFETY trial were labelled as: 1) the 
heart cluster (palpitations/fluttering and chest pain/discomfort): it was the most common 
symptom cluster occurring in 26% of participants; 2) the tired cluster 
(dyspnea/breathlessness, syncope/dizziness, weakness, fatigue/lethargy): all the 
symptoms were present in 14% of the subjects; 3) the vagal cluster (diaphoresis and 
nausea) occurred only in 3 patients. Over 50% of the participants with the tired cluster 
also reported experiencing the heart cluster.  
In spite of the differences in the number and composition of the clusters, the 
palpitations cluster78 or the heart cluster77, 82 was still the most common in both studies. 
The tired cluster and the weary cluster demonstrated the most similarity as they differed 
by only one symptom: chest pain was used in the weary cluster whereas in the tired 
cluster, weakness as a symptom was embedded. The observed differences in the clusters 
may be attributable to inclusion criteria, measurement error as well as recruitment 
strategies employed in both studies.78 These identified clusters have yet to be replicated. 
Although AF-specific symptom research is an emerging field,77, 76 some studies have 
already identified symptom clusters among AF patients76 and their relationship with 
health outcomes.79, 80, 81  
 
2.8 Clinical Assessment of Atrial Fibrillation 
To determine efficacious management of AF, it is essential to understand the 
underlying development of AF-related symptoms, i. e., how AF-related symptoms 
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change over time.15 Symptom fluctuation poses the biggest challenge when symptom 
patterns vary not only in different AF subsets but also in an individual patient.54, 52, 83  
Given the considerable variability of symptoms and their severity as well as 
treatment dependence on individual circumstances,36 a patient with suspected AF needs 
to undergo a thorough clinical assessment. Clinicians have to manage patients presenting 
with a variety of symptom severity, yet with “substantively similar physiology”.70 The 
hardest aspect of diagnosing AF is that the correlation between symptomatology and 
objective findings varies a lot for any given patient.70 As a result, it is challenging for 
clinicians to distinguish a set of typical cases to expect in terms of clinical manifestation 
in patients with AF.  
At the stage of clinical assessment of AF, one aims at establishing the type of 
AF, its etiology and time of onset. 36 It is important to explore major comorbidities and 
potential complications which would, in turn, affect the suitability of future treatment 
plans.  
The existing research provides very limited, if any, information on mapping the 
patient journey after the first visit to the general practitioner. Little is known about the 
sequence of decisions made “to identify, assess, manage and monitor patients with AF”.29 
Knowing common patient care pathways is crucial, particularly because they are evidence-
based and as such provide a “guide to the guideline” by informing clinician’s decision-
making. Unfortunately, multiple versions of guidelines for AF – both in North America and 
Europe – hardly reflect on real-life context within the primary care framework. While the 
clinical literature is rich and extensive, the individual variability mentioned in most 
guidelines underscores the need for a better understanding of the patient experience. 
 
2.9 Methods for Detecting Atrial Fibrillation 
The major methods currently used to identify pulse irregularity caused by AF can 
be classified in the following groups: 1) pulse palpation;37, 84, 85, 86, 87, 88 2) blood pressure 
monitors (BPMs);84, 89, 90, 91, 92, 93 3) and ECG37, 94, 95, 96, 97, 98, 84, 99, 87, 100.  
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In accordance with current guidelines,101, 102 pulse palpation should be used as 
the first step in screening for AF. Two randomized controlled trials in a primary care 
setting evaluated pulse palpation in combination with confirmatory 12-lead ECG and 
found it to be a cost-effective and efficacious method of AF screening.37, 86  
Nevertheless, pulse palpation is thought to be the least diagnostically accurate 
which is reflected by its lower specificity.103 This tendency can be explained by inter-
observer reliability when health care professionals are required to classify the pulse as 
being normal or irregular.103  
The range of sensitivity in most studies on pulse palpation was high: between 
91% and 100% whereas the specificity ranged from 70% to 77%. The pooled results of 
positive and negative likelihood ratios5  demonstrated that pulse palpation could 
moderately help in ruling in AF. However, in all the studies, the patient population was 
older than 65 years and the pulse was taken by a nurse, not a general practitioner. 
Therefore, it is difficult to generalize these findings to younger patients, with their pulse 
rate taken by a physician.     
Blood pressure monitors overcome the limitation of inter-rater reliability that can 
be misleading in the pulse palpation method. Any electronic device, including BPMs, 
uses rigid software algorithms with predetermined cut-off points. The BPM determines 
the severity of irregular pulse and classifies patients as meeting or non-meeting the 
inclusion criteria for AF. As a result, other non-AF-related causes of pulse irregularities 
are excluded by the software algorithms.103 
When compared to pulse palpation, BPMs are much more accurate in detecting 
patients with suspected AF. In a primary care setting, the use of BPMs is commonly 
advocated among patients being monitored for hypertension.104 Apart from being 
“simple, quick and accurate”, BPMs are also cost-effective and do not require any 
additional training. Since blood pressure monitoring is already integrated into 
cardiovascular screening protocols in primary care,103 BPMs can be a pragmatic 
substitute for pulse palpation.  
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The diagnosis of AF requires rhythm recording demonstrating irregular rhythm 
in the absence of organized atrial activity. The 10-second 12-lead standard ECG cannot 
register the typical episode of AF that lasts ⩾ 30 seconds. Ironically, for most trials that 
formed the evidence for guidelines, ECG-diagnosed AF was an inclusion criterion. 
However, following the 2007 consensus document on catheter and surgical ablation of 
AF that was adopted by the Heart Rhythm Society, the European Cardiac Arrhythmia 
Society and the European Heart Rhythm Association105, AF is defined as an arrhythmia 
lasting ⩾ 30 seconds106. Furthermore, the thirty-second gold standard definition of AF may 
lead to various predictive implications when detected on a 24-hour Holter monitor versus 
an implanted device106. 
For chronic forms of AF, ECG is a cost-effective and effective method of prompt 
recording of irregular heart rate.107  Substantive evidence also confirmed the 
effectiveness of ECG recording for silent, undetected AF. This type of AF is common, 
particularly for older patients and patients with heart failure.108 The adverse health 
outcomes of undiagnosed AF include stroke and rate-related cardiomyopathy, and 
patients with significant comorbidities and increased mortality more often have AF.109, 
110, 111 As a risk factor, AF is associated with mortality in patients with evidence of 
organic heart disease or systemic disorders. ECG monitoring 72 hours post-stroke112, 113 
or for longer periods114, 115 enhances the diagnosis of silent AF.  In older patient 
populations (over 75 years of age), short-term ECG on a daily basis increases detection 
of AF.116 It is unclear, however, whether early diagnosis changes management strategies 
for AF patients and more research is warranted in this direction.   
 
2.10 Drug Therapies After the Diagnosis of Atrial Fibrillation 
Once the clinical significance of arrhythmia is determined, pharmacological 
treatment of rate versus rhythm control is based on symptoms  Acute cardioversion is 
safe if the onset of AF is known to have been within 48 hours. Otherwise, one-month 
anticoagulation therapy followed by cardioversion or trans-esophageal echocardiogram 
(TEE) is required. The decision of initiating anticoagulation is dependent on the 
CHADS score and whether cardioversion is to be attempted. A patient presented to the 
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emergency department due to AF could be cardioverted electrically or with medications 
if the onset of AF is known to have been less than 48 hours. In cases of new onset AF, 
heart rate and rhythm can be controlled with anti-arrhythmic drugs as the first course of 
action.117 Anti-arrhythmic drugs are prescribed for most patients with no need of 
immediate cardioversion.117 Digoxin slows down ventricular heart rate but due to its 
slow onset, it is less effective in patients with high levels of adrenalin.118, 119  
 In an emergency department setting, beta-blockers and calcium-channel 
blockers can be administered intravenously120 as – irrespective of the patient’s 
sympathetic tone – they initiate a much faster response. These drugs are also synergetic 
with digoxin.121 However, they are very short-acting and must be followed by oral 
administration if they work and are tolerated. In a clinic, oral forms of calcium-channel 
blockers and beta-blockers are prescribed for newly diagnosed patients. 
When adequately high doses are used at the onset of AF, anti-arrhythmic drugs 
are generally effective in converting AF to normal sinus rhythm.122 However, the 
majority of these patients come back to sinus rhythm spontaneously within a 24-hour 
period of AF onset.123 
Anticoagulant therapy is prescribed when the onset of AF cannot be accurately 
determined in an emergency-department patient with the CHADS score of 0 .117 
According to the Canadian Cardiovascular Society’s (CCS) Atrial Fibrillation 
Guidelines (2010, 2012, 22014, and 2016)124, anticoagulant therapy is prescribed 
regardless in patients with the CHADS score of more than 0 or age 65 or over even 
when the time of onset is known.  Early anticoagulant therapy is key as patients with 
suspected AF are prone to blood clotting which can potentially lead to stroke.125, 126 The 
risk of clot formation among older AF patient populations (80-89 years of age) that do 
not receive anticoagulants can be particularly high and reach the value of 23.5%.127 To 
prevent stroke for the current and future episodes and regardless of the time of onset, the 
patient receives anticoagulant therapy.  
The choice of a specific anticoagulant drug is dependent on the type of AF, 
presence of comorbidities, patient’s adherence to the treatment plan as well as potential 
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drug interactions.125 Medication compliance is of particular importance as a missed dose 
increases the risk of thrombosis.128 
 
2.11 Indications for Referral of Patients with Suspected Atrial Fibrillation 
Referral pathways in AF are dependent on the type of AF and clinical 
manifestation of the disease (Table 1). For a small group of haemodynamically 
compromised patients at the onset of AF for less than 48 hours, the decision on 
immediate hospitalization is driven by the patient’s clinical presentation.These patients 
are referred for cardioversion within a 48-hour time-frame. The time window is key as 
the patients may be cardioverted without the subsequent need of anticoagulation.  
The referral pathway is tailored to individual needs of a patient and referral to a 
specialist is usually required. Due to high inter- and intra-individual diversity in clinical 
manifestation, it is difficult to define a typical case scenario for every type of AF. For 
instance, a patient with persistent AF is usually referred for elective cardioversion and 
for specialist advice to establish pharmacotherapy.29 Pharmacotherapy is also integrated 
in patient care for those diagnosed with permanent AF. However, not all AF patients are 
in need for pharmacotherapy and not everybody requiring pharmacotherapy will benefit 
from specialist advice.29 
 Davis et al.29 distinguished the following most common reasons for referrals: 1) 
failed medical treatment; 2) specific electrophysiological problems such as focal or 
slow, symptomatic AF or Wolff-Parkinson-White syndrome; and 3) lone AF. 
Due to its ambiguous and transient symptomatology or absence of such, the disease 
of AF is difficult to diagnose. In addition, there is a broad heterogeneity in precipitants of 
AF and diagnostic approaches. As a result, patients experience protracted assessment time. 
This adds to emotional distress and significantly disrupts their daily living as well as delays 
the start of evidence-based disease management. 
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Table 1: Indications for Referral of Patients with Suspected Atrial Fibrillation:2  
 
Type of Referral Indications for Referral 
   
Immediate / emergency referral 
• haemodynamic compromise at the onset of atrial 
fibrillation 
• atrial fibrillation for < 48 hours 
 
Early referral 
• onset of atrial fibrillation within 48 hours 
• patients with symptomatic atrial fibrillation 
 
 
 
 
Elective referral 
• paroxysmal atrial fibrillation 
• persistent atrial fibrillation for possible 
cardioversion 
• persistent or permanent atrial fibrillation for 
advice on pharmacotherapy 
• failure of medical treatment 
• Wolff-Parkinson-White syndrome 
• lone atrial fibrillation 
• focal or slow symptomatic atrial fibrillation, which 
may benefit from pacing 
 
 
 
  
  
                                                          
2 Davis M, Rodgers S, Rudolf M, Hughes M, Lip GYH. Patient care pathway, implementation 
and audit criteria for patients with atrial fibrillation. Heart. 2007;93(1):48-52. 
doi:10.1136/hrt.2006.099937 
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2.12 Patient-Centered Care and Lived Experience of Atrial Fibrillation 
There is a growing tendency to give equal considerations both to clinical practice 
perspective and to patients’ experiences, feelings, fears and expectations.129, 130, 131 At the 
core of the rhetoric around healthcare reforms is the philosophy and practice of patient-
centered care. Governmental agencies in Great Britain (National Health Service 2005),132 
in the USA (US Department of Health and Human Services 2008)133 and in Australia 
(Australian Commission on Safety and Quality in Healthcare 2012)134 along with the 
World Health Organization135 and multiple health policy and patient-advocating 
organizations around the world136, 137, 138 recognize the importance of prioritizing 
individual patient’s needs in medical care delivery.  
The first mention of patient-centered care was by Enid Balint in 1969139 who 
juxtaposed “illness-oriented medicine” to a different way of medical thinking also known 
as “patient-centered medicine”. In addition to establishing a medical diagnosis, the doctor 
needs to consider the patient in one’s wholeness in order to be able to form “an overall 
diagnosis”139. In Balint’s words, this two-fold task makes the doctor a general practitioner 
for some patients and “a minor psychotherapist” to others. It was when “the problem of 
the split doctor” was brought up for discussion. The question was whether such split was 
aimed at as it might have changed the whole medical approach of the general practitioners. 
Furthermore, doing “psychotherapy” with some patients would lead to the evolvement of 
new skills – both as psychotherapists and as detective inspectors. Enid Balint was the first 
researcher to challenge the traditional, taken-for-granted emphasis on the doctor’s 
perspective rather than on what the patient “tries to get from the doctor”139. 
The full publication of the patient-centred clinical method appropriate for family 
medicine was by Levenstein et al.140 in 1986. In operational terms, a rigorous patient-
centred method that is applicable to any family medicine situation, answers the question, 
“What is the minimum that can be expected of any family physician at any patient 
visit?”140 The authors’ firm belief140 is that it is essential for family medicine to develop 
such a method. 
Interestingly, in family medicine, a clear-cut diagnosis marks a failure, indicating 
missed opportunities for disease prevention. When the patient presents cues of unwellness 
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and the physician observes signs of the abnormality, the principle of an objective standard 
does not work. It is important to assess the patient in relation to one’s own norms rather 
than by an objective standard140.  
For the patient-centredness to be effectively integrated into the disease 
management which is “the quintessence of family medicine”141, the doctor needs to 
understand both the patient and the disease. Levenstein et al. stress that this two-fold 
purpose can only be achieved by including the process of differential diagnosis. At the 
same time, the physician needs to know individual life circumstances of the patient, his or 
her expectations, feelings and fears. Patient-physician interactions are best described in 
terms of the patient’s and physician’s agendas140. As the patient-centered method relates to 
the patient’s agenda, the physician sees the illness through the patient’s eyes by trying to 
enter the patient’s world. Simultaneously, the doctor applies his disease-centered agenda 
by bringing the patient’s problems into his clinical world of pathologies and diagnoses. 
According to Levenstein et al140, there is no risk of invading a patient’s privacy in 
this method if the doctor does not play the role of a detective inspector. Instead of probing, 
the physician poses open-ended questions for the patient to express one’s own feelings, 
expectations and fears. Through such an expression, the doctor gets the context of the 
illness that may be crucial to understanding of the whole illness.  
The concept of patient-centered care was further   developed by the Picker Institute 
in 1988142 and the existing scientific paradigm has already accumulated sufficient 
evidence of benefits of patient-centered care.129 It can improve patient-important 
outcomes,143, 144, 145, 146, 147 on the one hand, and reduce the workload and healthcare 
expenditures,148149 on the other hand, by avoiding services that patients may neither want 
nor need. From a legal standpoint, fewer malpractice lawsuits will occur150, 151 as person-
centered care increases patient satisfaction.152 Lastly, patient-centered care has ethical 
value of its own as it treats patients as persons with significance.153 
While there is no singular, universally accepted definition of person-centered 
practice, various health care groups tend to focus on its different aspects. This happens at 
all the levels – from an individual encounter level, through various management stages to 
policy activities.130 Being reflective of their professional interests and roles,130 different 
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stakeholders interpret patient-centered care in their specific ways. In order to 
operationalize this concept at the patient care level, it is key to explore the lived 
experience of patients. Without mapping the patients’ journey through their interactions 
with the health care system and across its organizational sectors, it is impossible to 
meaningfully apply the concept of patient-centered care to individual patients.   
Capturing patients’ experiences from the symptom onset to the definitive diagnosis 
of AF is needed not only for the sake of early management from the doctor’s perspective, 
but also for fear and uncertainty reduction, from the patient’s perspective. Each patient 
journey can be slightly or totally different from what physicians anticipate it to be. A 
standard case scenario would be the one of an emergency admission, with the arrhythmia 
documented on ECG and a clinical diagnosis obtained.  
A more typical experience, however, is characterized by delays in obtaining a 
confirmed diagnosis.154 The delays are attributable to transient episodes of AF that are 
difficult to “catch” on physical examination or to confirm by ECG. Shortness of breath, 
palpitations and loss of energy are generic symptoms with no objective explanation154 that 
are often interpreted by primary care physicians as insignificant and caused by stress.155 
Symptom vagueness and arrhythmic elusiveness significantly defy diagnosis, making 
some patients go to great lengths in validating their disease experience.154 As a result, 
patients perceive themselves to be a “bother” that is either dismissed or not believed.156  
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CHAPTER THREE – METHODS 
3.1 Objectives 
The objectives of this research were: 1) to characterize an AF episode of illness in 
terms of the number of physician visits, episode length, medications prescribed, diagnostic 
investigations ordered, and referrals made in a sample of Canadian family practice 
patients; and 2) to compare the findings with the control group of patients living with 
other chronic conditions by defining a magnitude of effect.  
Objective One: to characterize an AF episode of illness in a sample of Canadian 
family practice patients. 
Question 1: 
What is the mean and median number of physician visits in an AF episode of 
illness? 
Question 2: 
What is the mean and median length (in months) of an AF episode of illness? 
Question 3: 
a) How many medications are prescribed during an AF episode of illness? 
b) What medications are prescribed during an AF episode of illness? 
Question 4: 
a) How many diagnostic investigations are ordered during an AF episode of 
illness? 
b) What diagnostic investigations are ordered during an AF episode of illness? 
Question 5: 
a) How many referrals are made during an AF episode of illness? 
b) What referrals are made during an AF episode of illness? 
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Objective Two: to explore the differences between the study group and the control 
group in terms of the number of physician visits, episode length, medications prescribed, 
diagnostic investigations ordered, and referrals made as well as to measure an effect size. 
 
3.2 The Deliver Primary Health Care Information (DELPHI) Database as 
Source of Data 
De-identified, high-quality data for a 10-year period (2005 – 2015) from 23 
general practices in 10 primary care urban and rural practices from southwestern Ontario 
were extracted from the DELPHI (Deliver Primary Healthcare Information) database and 
further analyzed for the two objectives specified above. 
The DELPHI Project is an ongoing project with the starting date of 2003. The 
overarching goals of the project were:157 1) to facilitate information-sharing in 
interdisciplinary primary healthcare by developing an EMR system;  and 2) to define, 
evaluate and improve the quality of primary health care.  
Three types of structured data – symptoms, diseases and interventions - are coded 
in the DELPHI database which is similar to an analogous albeit larger database in the 
United Kingdom called the General Practice Research Database158. Twenty-three general 
practitioners in ten primary care urban and rural practices from southwestern Ontario were 
recruited into the DELPHI project. The constructed DELPHI database covers a wide 
geographic area of Ontario, stretching to Windsor in the south, to Kincardine in the north, 
to Brantford in the east and encompasses the London area. According to the DELPHI 
developers, 157 sex and age distribution of the participating physicians represents Ontario 
physicians as a whole, although the DELPHI sample of the participating physicians is less 
urban. Age and sex distribution of the patients also largely resembles the Canadian general 
population.  
Data extraction from each practice occurs quarterly. The extracted data include the 
billing code, family history, problem lists, interventions, medications, referrals, allergies, 
laboratory tests, immunizations, investigations and physical examinations for each patient.  
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On a random sample of patients with International Classification of Primary Care 
(ICPC)-coded data (please see Section 3.3, below), the following additional data 
components are extracted157: 1) up to five reasons for encounter (RFE) per visit coded 
within the vocabulary available in ICPC (codes 1-20 for each chapter); 2) up to five 
diagnoses per visit, and 3) non-chronic disease tracking within the framework of episodes 
of care. 
Each subsequent data extract is longer in its time-period than the previous extract 
because the longer period includes the time of both the previous and the new extract. In 
other words, the DELPHI database is re-created with successive cumulative extracts of 
electronic medical records each quarter of the year. For instance, at Extract 1 (at the very 
first data extraction since the launch of the DELPHI database), three months of data were 
extracted; at Extract 2, six months of data were collected (three previous months + three 
new months) and at Extract 3, nine months of electronic medical records were extracted 
(six previous months + three new months) and so on. The pooled database that is being 
refreshed on an ongoing basis, is referred to as the DELPHI database. 
A unique number is assigned to each patient record. The patient’s name, address 
and telephone number are not retrieved from the general practitioner’s office157. The only 
personal identifiers collected are partial date of birth, partial postal code and sex/gender157. 
Repeated data extraction is performed in such a manner that patients’ identification is not 
required. Consequently, it is impossible to identify either a participating physician, or a 
patient. Moreover, access to the database is restricted to personnel involved in DELPHI 
research projects and only after they have signed confidentiality agreements.   
 
3.3 The International Classification of Primary Care (ICPC) 
The International Classification of Primary Care (ICPC) is a classification system 
that was developed to categorize medical concepts into classes on the basis of their 
relevance for primary care159, 45 The basic structure of an encounter within an episode of 
illness distinguishes reasons for encounter, symptoms, complaints, diagnoses and 
diagnostic and therapeutic interventions160.  
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ICPC conversion structure with the International Classification of Diseases (ICD-
10) allows high specificity that is necessary in patient care161. For the use of expert 
systems and for retrieval purposes, ICPC structures computer-based patient records into 
the episode-oriented database. And a large nomenclature such as ICD-10 ensures the 
highest possible level of specificity of the individual diagnostic labels. Consequently, on 
the level of individual patients’ problem list, the complete conversion of ICPC and ICD-
10 ensures an optimal description of a patient’s clinical problems161. 
The twenty-two chapters of ICD-10 include blocks corresponding to different body 
systems: for instance, Chapter X corresponds to the diseases of the respiratory system 
whereas Chapter XV encompasses pregnancy, childbirth and the puerperium and so on. 
With its three core modes – a reason for encounter classification, a diagnostic 
classification and a process classification, - the ICPC is used as an instrument for 
identification and analysis of primary care elements. In application to this research, the 
ICPC allows to move to an episode-oriented epidemiology159, when transitions (changes) 
between encounters in an episode of care can be explored.  
To include the ICPC aspect in the DELPHI project, the selected electronic health 
record (EHR) company modified the existing EHR. As a result of the ICPC-related 
modifications, the participating physicians needed to enter additional information that was 
outside of their routine recording in the EHR. That was why the DELPHI personnel first 
familiarized the health care providers with the core EHR functions162: the participating 
sites received training in the entry of clinical data, billing and scheduling. Furthermore, 
prior to the ICPC inclusion, the EHR was implemented for at least one year162. 
Once the participants became proficient in their daily use of  EHR, they were 
introduced to the research specific data modifications162. The DELPHI personnel provided 
specific examples to the participating sites to reinforce the importance of entering as much 
as possible in the corresponding fields in the database. For instance, the results of the 
physical examination performed in the office are to be entered into the “physical signs” 
module rather than as narrative text in the notes field.  
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To assess the degree to which all the EHR components were used for entering 
appropriate data, audits were run. The identified weaknesses informed further, more 
specific training that was offered either by the DELPHI staff or by the EHR company. For 
the purpose of collecting reliable research data, only the health  care providers (and not the 
administrative staff)162 were asked to identify the relevant ICPC codes.   
To further ensure data reliability, a three-phase ICPC training process was 
implemented162. 
 At the first phase, the trainer reviewed ICPC-related theory with up to six 
participants and provided multiple examples over a period of 1.5 hours. For future 
reference, the participants received a laminated colour-coded list of ICPC code names, a 
thirty-page ICPC manual, and a bound list of ICPC codes with descriptive details.  
At Phase Two, fifteen previously developed clinical vignettes were distributed to 
the participating sites with a request to identify ICPC codes that are relevant – in regards 
to diagnosis and reason for encounter - to each case. Base on the results, inter-rater 
reliability was assessed. Another set of fifteen vignettes was distributed among the 
participants, after they got some experience in coding their actual encounters. Similarly, 
these codes were used for the comparison of inter-rater (among the participants)  as well 
as intra-rater reliability (when compared to the initial results)162.  
At the final 1.5-hour stage of training, the instructor demonstrated the correct use 
of ICPC-related software that captures reason for encounter and diagnosis fields. Another 
goal of the final stage of training was to ensure that the participants gained an 
understanding of the episode of care structure within the EHR framework.  
Approximately 10% of the DELPHI patient population was coded using ICPC. A 
‘ramp-up’ method for coding ICPC data was implemented in order to simplify the process 
for the physicians who were building up their confidence in using a new coding system. A 
few patients from the physician’s list were randomly selected every day and then coded 
using ICPC. For obtaining a longitudinal record, once a patient was selected, each 
subsequent physician visit was ICPC-coded. 
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3.4 Episodes of Atrial Fibrillation Illness Defined Using ICPC-Coded Data 
An episode of AF illness is defined as an inclusive number of days between the 
first ICPC-coded encounter and the date of AF diagnosis. An episode length was 
calculated by taking the difference in number of days between the starting point and the 
end-point of an episode of illness, with the addition of one day to include the first and the 
last day. 
To identify patients with the diagnosis of AF, the International Classification of 
Primary Care (ICPC, 2nd edition) code K78 (“atrial fibrillation/flutter”) was used. Since 
this research was conducted within the framework of an episode of illness, there was a 
need for accurate registration of physician visits in general practice. The focus was on the 
reasons for encounter, the diagnoses and the interventions. These three components form 
the core of an episode of illness and the ICPC provides detailed coding for them in EMR 
data161.  
 
3.5 Look-Back Period and Left-Censored Data 
The choice of the type of a look-back period considerably impacts the number of 
identified incident cases and depends on the research question and available data. As far as 
the duration of a disease-free period is concerned, Czwikla et al.163 recommend using - if 
data permit - a fixed-window look-back period of two years and more. A sufficiently long 
disease-free period prior to diagnosis would allow one to distinguish incident cases from 
recurrent and prevalent ones164 and prevent incidence overestimation.165 Of note, Schubert 
et al.165 stress that three years of looking back can still lead to incidence overestimation. 
Informed by the current research,166 the decision was made to use an all-available 
rather than a fixed-window look-back period. A fixed-window look-back period has 
limitations of its own and needs to be at least 1 year in length when used.167 Since there is 
a defined study entry date (first diagnosis of AF), the use of all historically available 
baseline information for each subject helps get an analytical sample of incident cases. All 
the patients had available data for at least 6 months prior to diagnosis (the look-back 
period) and differed in lead-up time before that period.  
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It is often impossible to distinguish an absence of the condition from missing 
data.166  Commonly and operationally, missing data indicate that the condition is not 
present.168 However, if the diagnosis of AF has been established before the patients’ 
enrollment into the DELPHI database, it means that the data are left-censored. In this 
instance, misclassification of incident cases163 and, thus, introduction of bias occurs. It is 
particularly relevant to administrative data. We considered the possibility of left censoring 
in the DELPHI database because the goal of DELPHI data collection was individual 
patient care, not research.157 Only the cases with the documented diagnosis of AF were 
included as it is considered to be a resilient case definition for incidence estimation.165  
 
3.6 Definition of Independent Variables 
3.6.1 Study Group 
For the purpose of this research, the full sample of 69 patients with ICPC-coded 
first-time diagnosis of AF (K78) comprises the study group.  
 
3.6.2 Control Group 
For Objective Two, an independent-samples t-test was performed to compare the 
mean scores on the following dependent continuous variables – the number of physician 
visits, the episode length, the number of medications prescribed, the number of diagnostic 
investigations ordered, and the number of referrals made for two distinct groups of 
patients – an AF group (the group of our primary interest) and a comparison group. 
There are several steps involved in defining a comparison group which have been 
informed by the review of literature on multimorbidity. Primarily, our decision has been 
informed by Fortin, Almirall & Nicholson169. The comparison group is composed of nine 
smaller groups of patients who are first ever diagnosed with one of the nine most 
prevalent chronic conditions/categories of conditions in Canada. Each of the nine 
mutually exclusive groups has more than 100 patients. These chronic 
conditions/categories of conditions169 include hypertension; depression or anxiety; 
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chronic musculoskeletal conditions causing pain or limitation; arthritis and/or rheumatoid 
arthritis; osteoporosis; asthma, chronic obstructive pulmonary disease (COPD), or 
chronic bronchitis; cardiovascular disease (angina, myocardial infarction, atrial 
fibrillation, poor circulation in the lower limbs); heart failure (including valve problems 
or replacement); and stroke and transient ischemic attack. For the purpose of comparison, 
a group of patients from firstly diagnosed AF are excluded.  
The pre-defined criteria that initially informed the selection of chronic conditions 
and that are presented in the above mentioned article are coherent with our overarching 
goal of exploring an AF patient journey in the primary care setting. They are:169 1) 
relevance to a primary care setting; 2) impact on patients; 3) high prevalence in primary 
care; and 4) high prevalence of occurrence in the existing body of literature. Grouping 
related conditions under one category to be more flexible and inclusive of them is another 
reason why we have adopted this approach for creating our comparison group. It also 
allows comparability among studies that use the same criteria of creating comparison 
groups or rely on the same measuring tool of comorbidity. 
The first visit day and the day of diagnosis are used to calculate an episode length 
and, subsequently, the number of physician visits, medications prescribed, diagnostic 
investigations ordered, and referrals made within an episode of illness.  
The 90-day lag period after the date of diagnosis is used for the number of 
referrals and diagnostic investigations.  
 
3.7 Definition of Dependent Variables 
Five dependent variables were created: the number of physician visits, the episode 
length, the medications, the diagnostic investigations, and the referrals. The number of 
physician visits variable was coded using ICPC diagnostic codes within the pre-defined 
framework of an episode of illness. Except for the ICPC component of the electronic 
medical records, longitudinal records of patients’ medications, diagnostic investigations 
and referrals were used to construct medications, diagnostic investigations, and referrals 
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variables. To meet the first objective of the research, the descriptive statistics for the five 
dependent variables are provided.  
 
3.7.1 Number of Physician Visits 
The number of physician visits is a count variable that is defined as the number of 
in-office physician visits within the framework of an AF episode of illness. In the study 
group, there were no patients with a one-visit episode of illness. The minimum number of 
physician visits was 2 visits per an episode of illness and three of the patients were 
fortunate to be diagnosed within a two-visit time period. 
 
3.7.2 Episode Length 
The episode length is a count variable that is defined as an inclusive number of 
days between the first ICPC-coded physician visit and the physician visit during which 
the diagnosis of AF was confirmed. 
There was not a single one-day episode length. This variable was calculated by 
getting the time difference between the date of diagnosis and the date of the first ICPC-
coded physician visit within the framework of an episode of illness for each of the 69 
participating patients. Consequently, 69 episodes of illness were defined in 69 patients, 
with each of them having their varying episode length. 
 
3.7.3 Medication 
 The medication variable is defined as the number and type of AF-specific 
medications prescribed during the episode of illness. For Objective One (to characterize 
an AF episode of illness for in a Canadian primary care setting), medication is defined as 
a count variable. The choice of the two drug groups is based on the conducted review of 
current treatment strategies of AF117. If promptly administered and at an adequately high 
dosage, antiarrhythmic drugs are effectively used to convert AF to normal sinus 
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rhythm170. To prevent blood clot formation in the atria, anticoagulant therapy is 
essential126. 
This variable captured the AF-specific medication prescriptions that were 
recorded in the electronic medical records (EMRs) during physician visits within an 
episode of illness.  
To confirm relevance of identified medications to an AF episode of illness, each 
drug title was queried on HealthyOntario.com. It is a Canadian government-sponsored 
health information site that promotes greater individual responsibility for well-being by 
addressing everyday health concerns in layman’s terms171. As far as medication is 
concerned, HealthyOntario.com is a helpful resource of ensuring medication review and 
safety in order to decrease rates of “near misses”172. A “near miss” is an event in 
medicine that had the potential of resulting in harm to the patient but did not occur 
because of the timely intervention by the patient, the physician or the family member, or 
due to good fortune. “Near misses” are also known as "good catches" or “close calls”. 
 
3.7.4 Diagnostic Investigation 
The diagnostic investigation variable is defined as the number and type of 
diagnostic investigations performed within an episode of illness. To meet Objective One 
(to characterize an AF episode of illness in Canadian family practice), this variable is 
labelled as a count variable. 
By its major types, the diagnostic investigation variable has the following 
categories that are initiated in a primary care setting29: clinical assessment, basic blood 
tests (including thyroid function tests), chest X-rays and an electrocardiogram (ECG). We 
expect to see ECG as a diagnostic test for many patients diagnosed with AF as, according 
to current guidelines for the diagnosis of AF, confirmation of the  arrhythmia through 
ECG, telemetry, or portable heart rhythm recorder is essential29.  However, the best 
practice guidelines may not necessarily be followed as was revealed by a study 
describing the management of prevalent cases of atrial fibrillation in two UK practices. 
The authors reported a suboptimal use of standard diagnostic investigations, with only 
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18% of the patients receiving an ECG close to the date of their first diagnosis173. More 
specialized diagnostic investigations such as electrophysiological studies may require a 
referral to a secondary care clinical setting. Some general practitioners, however, have 
open-access echocardiography in their offices, which should significantly expedite 
assessment of patients for functional and structural heart disease29. 
 
3.7.5 Rationale for Lag Period in Definition of Diagnostic Investigation 
In the sample of 69 patients, there were instances when it was impossible to link a 
diagnostic investigation to the physician visit during which it was ordered. Missed 
appointment dates is another challenge that makes it impossible to associate a specific 
diagnostic investigation with a specific physician visit. Moreover, the date of record 
creating could denote several options ˗ the date of the investigation being ordered, the 
date of the appointment being booked, or the date of inputting diagnostic results into the 
EMRs. Although the date of record creating did not have any missed value, it still lacked 
interpretative power. In order to resolve this issue, a lag period of 90 days was 
incorporated into the variable definition.  
 
3.7.6 Referral 
The referral variable is defined as the number and type of referrals made during 
the episode of illness. To meet Objective One, the referral variable is defined as a count 
variable.  
A referral was included in the episode of illness if the date of the referral was 
recorded between the starting and end-points of the episode of illness plus a 90-day lag 
period. Both AF-related and non-specific referrals were included into the episode of 
illness.  
In order to define AF-specific referrals, additional components of the EMR were 
explored to determine the type of information recorded in the EMR and the mode of its 
categorization. A referral record was a separate dataset in the EMR extract and provided 
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the following information: a type, purpose, an appointment date of referral (with the 
name of the referred physician), a date of record creation, and an encounter number to 
bind the referral with the schedule of physician visits.  
The referral dataset included all the referrals recorded for the patient, regardless 
of the underlying reasons for the referrals. Both AF-specific and non-specific referrals 
recorded within the episode of illness were included in the subsequent analyses.  
 
3.7.7 Rationale for Lag Period in Definition of Referral 
The same rationale for a 90-day lag period applies in definition of both the 
referral and diagnostic investigation variables. 
 
3.8 Data Analysis Objective One: Characteristics of an Atrial Fibrillation 
Episode of Illness 
IBM SPSS Statistics 25 software was used for statistical analyses conducted on 
the entire sample of 69 patients with firstly diagnosed AF. Correspondently, 69 complete 
episodes of AF illness were identified for subsequent analysis.  
To minimize measurement biases in statistical analyses, each variable in the data 
file was checked for errors. To do so, the frequencies for all the variables were inspected. 
It allowed to ensure that there were no values falling outside the range of possible values 
for each specified variable. 
 
3.9 Data Analysis Objective Two: Comparison of Study Group and Control 
Group.  
3.9.1 An Independent-Samples T-Test 
As we would like to compare the mean scores of the five continuous dependent 
variables in the study group with the mean values from the control group, an 
independent-samples t-test is an appropriate statistic.  
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3.9.2 Underlying Assumptions for an Independent-Samples T-Test174  
Level of Measurement: It is assumed that each dependent variable uses a 
continuous scale instead of discrete categories. At the initial stage of the research 
planning, a decision was made to give a preferential choice to continuous dependent 
variables. It gave us a wider range of techniques to choose from for data analysis.  
Random Sampling: The scores are assumed to be obtained from a random 
population sample.  
Independence of Observations: The observations are assumed to be statistically 
independent of one another, i. e., not influenced by any other measurement or 
observation.  
Normal Distribution: The populations from which the samples are taken are 
assumed to be normally distributed. This is often not the case in real-life research as 
scores on dependent variables can be not normally distributed. However, with a relatively 
large sample size (more than 30), approximately normal distributions are sufficient. 
Moreover, most statistical techniques are robust to this assumption. 
Homogeneity of Variance: Samples are assumed to be obtained from populations 
of equal variances. In other words, the variability of scores in each group is expected to 
be similar.  
 
3.9.3 Effect Size Statistics 
Following the guidelines of the fifth edition of the American Psychological 
Association (APA), effects sizes are reported for Objective Two: “it is almost always 
necessary to include some index of effect size or strength of relationship in your results 
section, for the reader to fully understand the importance of your findings”175. Similarly, 
Snyder and Lawson176 emphasize that it is impossible to predict an effect size based 
entirely on statistically significant results. In unison with them, Thompson177 and 
Volker178 believe the effect size to be critical information that cannot be assessed by 
considering only a P-value. 
42 
 
Being a function of both an effect and sample size, a small P-value can relate to 
any magnitude of effect179. With a large sample size, the likelihood of getting a 
statistically significant difference is increased. However, a small P-value might not mean 
a large effect size. Conversely, a modest study can generate a large effect, regardless of 
its statistically insignificant findings that are the direct consequence of the small sample 
size176, 179. 
In the absence of previously reported effect sizes for the dependent variables of 
interest in the literature (the number of physician visits, the episode length, the 
medication prescribed, the diagnostic investigation ordered, and the referral made), a 
decision was made to report several common effect size statistics and to compare the 
results between them: Cohen’s d, eta-squared, Glass’ delta, and Hedge’s g. All the 
measures of effect size are used to interpret the strength of association between the group 
variable as an independent variable and each of the five dependent variables. Moreover, 
reporting multiple effect sizes to address the same question improves the communication 
of the results180. 
 
3.9.4 Missing Data 
There were no missing data for any of the variables included in the analysis. 
 
3.9.5 Outlying Points 
Since many statistical techniques are sensitive to outliers,181 it is essential to check 
for cases with values significantly below or above the majority of other cases. This was 
done by inspecting the residuals in the Residuals Statistics table. 
Another statistic used for assessing the presence of outliers was the 5% trimmed 
mean, when the software removed the top and bottom 5 per cent of the cases and 
calculated a new mean value.181  
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CHAPTER FOUR – RESULTS    
4.1 Sample Description 
The sample consists of 69 complete AF episodes of illness extracted from the 
ICPC-coded part of the DELPHI database over a four-year period, between October 
2005 and September 2009. A summary of patient- and episode-level characteristics is 
presented in Table 2. This table also contains information on the top five most common 
chronic conditions. 
From the output generated by IBM SPSS, by biological sex, there are 35 females 
(50.7%) and 34 males (49.3%), giving a total of 69 patients. By age, the patients range 
between 50 and 95 years old at the time of their diagnosis, with a mean of 75.83 and a 
standard deviation of 10.68. Only 5% of the patients are younger than 55 years of age 
and another 5% are above the age of 90. 25% of them are not older than 71 years of age 
at the time of diagnosis. Another 25% of the patients are older than 83 years of age.  
Out of the ten practices participating in the DELPHI project and contributing their 
patient-level data to the DELPHI database, only seven practices had ICPC-coded data 
on first-time-diagnosed AF patients. 28 patients (40.6%) were seen in one rural primary 
care practice whereas 41 patients (59.4%) visited six urban practices, thus 
demonstrating a higher clustering of cases in the urban setting.  
Three practices (one rural and two urban) accounted for 88.4% of all the cases. Of 
the 88.4%, slightly more cases (by 7.2%) were diagnosed in the two urban practices 
than in the one rural practice. There were 33 urban cases (47.8%) compared to 28 cases 
(40.6%) in the rural setting.  
When further analyzed by the doctor’s code, 40.6% of the 69-patient sample (28 
cases) were diagnosed by two doctors in the single rural practice that is presented in the 
sample. Surprisingly, one doctor in this particular practice diagnosed AF in 20 patients, 
thus accounting for 29.0% of all the cases in the sample. 
The larger of the two urban practices added another 25 cases (36.2%) to the 
sample. There were five diagnosticians in total in that practice, with three of them 
having identified one new case each (4.2%) and one of them having established the 
diagnosis of AF in two patients (2.9%). Similarly, there was a doctor in the practice 
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who identified 20 incident cases, thus contributing another 29.0% of patients to the 
final sample.  
The much smaller urban practice – in terms of its contribution of cases – had only 
one doctor who identified 8 new cases of AF (11.6% of the sample). 
Only 27.5 % (19 cases) do not have any comorbidities, i.e., they have a single 
diagnosis of AF; the mean number of diagnoses is 6.74, with a standard deviation of 
7.41.  
As the literature considers the reason for encounter to be a practical source of 
patient information161, we have decided to include it for a more detailed description of 
the sample. Furthermore, ICPC contains over 200 complaints and symptoms serving the 
categorization of both clinical findings and reasons for encounter161.  
The reasons for encounter are registered in the ICPC-coded portion of the 
DELPHI database in the form of ICPC codes. The five most prevalent reasons for 
encounter are 1) blood test; 2) weakness/tiredness general; 3) 
medication/prescription/renewal/injection; 4) hypertension uncomplicated; and 5) 
medical examination.  
There are two broad classes of reasons for encounter: 1) procedural or diagnostic 
and 2) therapeutic interventions. It is important to distinguish between the two of them 
as a specific type plays a crucial role in explaining the differences in the intervention 
distribution within an episode framework49. It is also the case that these two classes 
may be mixed. They are not mutually exclusive in that patients may come requesting a 
procedure or in need of a diagnosis, but also undergo an intervention. 
Procedural reasons for encounter include, for instance, patient’s requests for 
interventions, a referral to a specialty outpatient clinic/tertiary care hospital, an X-ray of 
different body parts (as the most common type of diagnostic investigation), a 
medication prescription or renewal, etc. Given the proportion of the patients studied 
who had multiple chronic conditions, the most common procedural reason for 
encounter was medication renewal.  
Out of the total 361reasons for encounter in the sample, 298 (82.5%) were 
procedural in nature. This finding has important implications for clinical care, as 
patients are no longer seen as passive recipients of medical services but rather active 
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participants in diagnosis and treatment. They are able to identify their own needs and 
request the services that they believe to be beneficial to their health and well-being. In 
other words, patients shape the content of primary care45. As a result, primary care 
physicians – those in general practice, pediatrics, family and internal medicine182 – 
although performing a gatekeeper function, are inclined to satisfy their patients’ 
requests183. The high number of procedural reasons for encounter at the first date of AF 
diagnosis is highly suggestive of this tendency. Less than 20 per cent of the reasons for 
encounter are initiated due to patients’ symptoms and complaints at the date of AF 
diagnosis. This means that for the overwhelming majority of AF patients in the sample, 
the disease of AF does not have clinical manifestation that could be self-reported in the 
form of symptoms.   
Comorbidity is defined as “a distinct additional clinical entity”184.In terms of the 
presence of comorbidities, approximately 20 per cent of the patients did not have any 
other comorbidities: AF was a first chronic condition they have ever been diagnosed 
with. Forty per cent of the patients, however, had been diagnosed with 2 to 3 chronic 
conditions. A relatively large number of patients (16%) were diagnosed with five or 
more chronic conditions.  
The five most prevalent comorbidities account for 72.4% of all the comorbidities 
recorded in the sample. The five less common chronic conditions represent 16.8% of 
the total number of comorbidities. As expected, the top two of these – cardiovascular 
disease and hypertension – are cardiac related. The other three from the top five chronic 
conditions ˗ arthritis, chronic musculoskeletal and diabetes - are likely to be age-related 
as the mean age at diagnosis is 75.8 years of age. The five less prevalent chronic 
conditions accounted only for 16.8% of the total number of chronic conditions. 
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Table 2: Description of Sample 
 
Characteristics  Central Tendency and 
Dispersion/Type  
Frequency (%) 
Patient-Level  
Characteristics  
 
Age at Diagnosis (years)  
  
 
Mean   
Std. Deviation 
Percentile 5 
Percentile 25 
Percentile 50 
 
 
Minimum 
Maximum 
Range 
 
50-60 years   
61-70 years 
71-80 years 
81-90 years 
91-95 years 
  
 
75.8 years 
10.7 years  
55 years 
71 years 
77 years 
 
 
50 years 
95 years 
45 years 
 
9 (13.0%) 
8 (11.6%)  
27 (39.2%) 
23 (33.3%) 
2 (2.9%)   
Sex  Male  34 (49.3%)  
 Female  
  
35 (50.7%)  
  
 Episode-Level  
Characteristics  
  
 
Practice Type 
  
  
Urban  
  
  
41 (59.4%)  
28 (40.6%)  
 
    
Rural  
 
  
Number of Practices 
  
  
Urban  
Rural  
  
6  
1  
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Table 2: Description of Sample Continued 
Characteristics  Central Tendency and Dispersion/Type  Frequency (%)3 
Episode-Level  
Characteristics  
 
Number of Cases by 
Doctor’s Code 
 
 
 
 
 
 
 
Distribution of  
Reasons for Encounter 
at First Date of 
Diagnosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Description of Top 6 
Reasons for Encounter 
at First Date of 
Diagnosis 
 
 
 
  
 
Practice 004-14  
Practice 004-2 
Practice 009-1 
Practice 009-2 
Practice 009-3 
Practice 009-4 
Practice 009-5 
Practice 010-1 
 
0 reason for encounter 
1 reason for encounter 
2 reasons for encounter 
4-6 reasons for encounter 
8-10 reasons for encounter 
13-18 reasons for encounter 
Total # of reasons for encounter 
 
Mean 
Std. Deviation 
Minimum 
Maximum 
Range 
Percentile 25 
Percentile 50 
Percentile 75 
 
 
Medication/prescription/renewal/injection   
Blood test 
Weakness/tiredness general 
Hypertension uncomplicated 
Medical examination/health evaluation 
Preventive immunization/medication 
  
 
8 (11.6%) 
20 (29.0%) 
1 (1.4%) 
2 (2.9%) 
1 (1.4%) 
1 (1.4%) 
1 (1.4%) 
8 (11.6%) 
 
34 (9.4%) 
75 (20.8%) 
35 (9.7%) 
89 (24.6%) 
73 (20.2%) 
55 (15.2%)  
361 
  
5.91 
5.43 
0 
18 
18 
1 
4 
9 
 
 
28 (7.7%) 
13 (3.6%) 
11 (3.0%) 
10 (2.8%) 
9 (2.5%) 
9 (2.5%) 
    
                                                          
3 The percentage of “description” is the number of episodes of illness with a reason for encounter from the total 
episode of illness sample. It may not add up to 100% as some episodes of illness have a few reasons for encounter 
whereas others have none. 
4 The first three digits indicate the practice number and the last digit refers to a doctor in that practice. 
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Table 2: Description of Sample Continued 
Characteristics  Central Tendency and Dispersion/Type  Frequency (%)5 
Episode-Level  
Characteristics  
 
Reasons for Encounter 
at First Date of 
Diagnosis 
 
 
Chronic Conditions 
 
 
 
 
 
 
 
 
Distribution of 
Chronic Conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
Description of Top 5 
Chronic Conditions 
 
 
 
  
 
Symptom-free (procedural) 
Symptoms & complaints 
Total # of reasons for encounter 
 
 
Mean 
Std. Deviation 
Minimum 
Maximum 
Range 
Percentile 25 
Percentile 50 
Percentile 75 
 
1 chronic condition 
2 chronic conditions 
3 chronic conditions 
4 chronic conditions 
5 chronic conditions or more 
Total # of chronic conditions 
 
1 chronic condition 
2 chronic conditions 
3 chronic conditions 
4 chronic conditions 
5 chronic conditions or more 
Total # patients 
 
 
CVD 
Hypertension 
Arthritis 
Chronic Musculoskeletal 
Diabetes 
 
  
 
298 (82.5%) 
63 (17.5%) 
361 
 
 
4.34 
2.59 
1 
11 
10 
2 
3 
6 
 
15 (7.2%) 
40 (19.3%) 
51 (24.6%) 
24 (11.6%) 
77 (37.3%) 
207 
 
15 (21.7%) 
20 (29.0%) 
17 (24.6%) 
6 (8.7%) 
11 (16.0%) 
69 
 
 
83 (40.1%) 
29 (14.0%) 
15 (7.2%) 
13 (6.3%) 
10 (4.8%) 
 
   
 
                                                          
5 The percentage of “description” is the number of episodes of illness with a chronic condition from the total episode of illness sample. It may not 
add up to 100% as some episodes of illness have a few chronic conditions whereas others have none. 
49 
 
Table 2: Description of Sample Continued 
  
Characteristics  Central Tendency and Dispersion/Type  Frequency (%) 
Episode-Level  
Characteristics  
 
5 Less Prevalent 
Chronic Conditions 
 
 
 
 
 
 
 
 
 
  
 
Asthma/COPD6/Bronchitis 
Heart Failure 
Depression/Anxiety 
Hyperlipidemia7 
Cancer 
 
 
  
 
9 (4.3%) 
9 (4.3%) 
7 (3.4%) 
5 (2.4%) 
5 (2.4%) 
 
 
 
  
                                                          
6 COPD chronic obstructive pulmonary disease 
7 Hyperlipidemia – a high concentration of lipids or fats in the blood  
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4.2 Objective One: Characteristics of an Atrial Fibrillation Episode of Illness 
To complete Objective One of the thesis, Table 3 summarizes important findings 
that characterize an AF episode of illness in general practice. There was not a single one-
visit AF episode of illness in the sample of 69 patients, i.e., none of the patients were 
diagnosed with this chronic condition by the end of their first doctor’s appointment that 
was also a first ever ICPC-coded visit in the DELPHI database. It took approximately 10 
per cent of the patients up to 5 physician visits before AF diagnosis. In the middle of the 
spectrum were another 35 per cent of the patients who paid between 11 and 20 visits to 
their family doctors before receiving their diagnosis. A striking and somewhat 
unexpected finding is that 37.7% of the patients had 26 visits or more after which an 
established diagnosis of AF was shared with them.  
As far as the episode length is concerned, none of the patients were diagnosed 
with AF within an eight-month period and only 1 of 69 patients knew by the end of the 
ninth month that he or she had this condition. Over 40 per cent of the patients got 
diagnosed a year and a half later. Another 38 per cent of the patients received a diagnosis 
of AF after 20 to 49 months. About 8% of the patients (6 out of 69 patients) (8.5%) got 
diagnosed with AF after 50 months or more. 
A substantial number of medications (with the mean of 21.1 and the standard 
deviation of 12.8) was prescribed within all the episodes of illness. There was not a single 
episode of illness in which no medication was prescribed. A small portion of patients 
(7.2%) was prescribed a moderate number of medications (compared to the rest of the 
sample), i. e., 1-5 medications. There was another 10 per cent of the patients who got 
prescribed 21 medications and more. Diuretics (6.6%), anticoagulant medication (6.2%), 
and beta-blockers (4.4%) were most commonly prescribed. The minimum number of 
medications was 1 and the maximum number was 46, giving a wide range of 45 
medications. 
Different diagnostic investigations were ordered for about 52 per cent of the 
patients. Consequently, approximately another half of the patients (47.8%) did not 
undergo any diagnostic investigations. It is important to note that ECG as a cardiac-
specific diagnostic tool comprises only 14.9% of the total number of investigations. 
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Twenty five ECGs were done for 16 patients. It is also worth mentioning that 11 out of 
25 ECGs were performed on two patients (7 and 4 ECGs, respectively) and the majority 
of the “ECG patients” attended a single rural practice. So in the sub-sample of 36 patients 
undergoing any type of diagnostic investigations, only 16 patients were prescribed ECG 
as a cardiac-specific investigation. In other words, 44.4% (16/36) of those experiencing 
diagnostic investigations of any sort, had ECGs performed throughout their journey to the 
diagnosis of AF.  
For our patient sample, the most commonly utilized type of investigation was an 
X-ray of different body parts. Out of the patients that were sent for further diagnostic 
investigations (i.e., half of the sample), 50 per cent had fewer than four investigations and 
25 percent had more than eight diagnostic investigations. 
For the total sample of 69 patients, there were 106 referrals, i.e., less than 2 
referrals per each patient (106 referrals/69 patients = 1.5). Almost half of the patients 
(46.4%) were not referred to any secondary/tertiary care service. So if we take only the 
patients who did get referred to medical services outside their family physicians’ offices 
(37 patients), we will get the proportion of 2.9 referrals for each referred patient: 106 
referrals / 37 referred patients = 2.9 referrals for each referred patients.  
By looking closely at the referral types, one can see that cardiology referrals make 
only a small proportion of 5.7% of the total number of referrals. By going even further 
into the data, one can find that the six referrals to the cardiologist were made for 5 
patients attending the single participating rural practice that contributes 28 patients or 
40.6% of the total sample size. There was no cardiac-specific referral made in any of the 
six participating urban practices. 
30 per cent of the patients had one referral within their episodes of illness. 10 per 
cent had two referrals and another 10 per cent of the patients were referred three times 
within the framework of an AF episode of illness. A very small proportion of patients 
(4.3%) had a large number of referrals (over 13 referrals).  
As far as the description of the referrals is concerned, cardiology referrals are at 
the bottom of the list for the top six referrals and comprise only 5.7% of the total number 
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of referrals. Internal medicine as the most common referral type (19.8% of the total 
number of referrals) followed by referrals for orthopedic (11.3%) and vascular surgery 
(10.4%). Among less common types of referrals that still make to the top-six list are 
dermatology and neurology, with 10.4% and 4.7% of the total number of referrals, 
respectively.  
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Table 3: Episode of Illness Characteristics  
 
Characteristics Central Tendency & 
Dispersion / Type 
Frequency (%) 
  
Number of  Physician 
Visits  
  
2 visits 
3 visits  
4 visits  
6 visits 
7-15 visits 
17-30 visits or more 
31 visits or more 
Total # of visits 
 
 
Mean  
Median  
Std. Deviation 
Minimum 
Maximum 
Range  
 
  
6 (0.4%) 
4 (0.3%) 
19 (1.3%) 
14 (0.9%) 
316 (21.2%) 
440 (29.5%) 
688 (46.1%) 
1487 
 
  
32.2 
30 
19 
2 
75 
73 
 
 
7 (10.2%) 
11 (15.9%) 
14 (20.3%) 
11 (15.9%) 
26 (37.7%) 
69 
 
 
20.8 
16 
15.7 
3 
52 
49 
 
 
  
0-5 visits  
6-10 visits 
11-15 visits 
16-20 visits 
21 visits or more 
Total # of patients 
 
 
Mean 
Median  
Std. Deviation 
Minimum 
Maximum 
Range 
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Table 3: Episode of Illness Characteristics Continued 
 
Characteristics  Central Tendency & 
Dispersion / Type  
Frequency (%) 
 
Episode Length (months)  
  
1-8 months 
  
0 (0%)  
 9 months  1 (1.4%)  
 10-19 months 29 (41.9%)  
 20-29 months  13 (18.7%)  
 30-39 months 14 (20.1%)  
 40-49 months  6 (8.5%)  
 50 or more months  
Total # of patients 
6 (8.5%) 
69  
 
Mean   25.9 
 Median  
Std. Deviation 
Minimum 
Maximum 
                    22 
                    13.7 
                    9 
                    56 
  
Range  
  
                    47  
  
  
Distribution of 
Medications  
  
 1 medication 
2 medications  
3 medications  
4 medications 
5-10 medications 
11-15 medications 
16-20 medications 
21-46 medications  
  
1 (0.1%) 
2 (0.1%)  
10 (0.5%)  
9 (0.5%) 
378 (20.4%) 
427 (23.1%) 
324 (17.6%) 
694 (37.7%) 
 
 
 
  
Total # of medications 
 
Mean 
Median 
Std. Deviation 
Minimum 
Maximum 
Range 
 
1-5 medications 
6-10 medications 
11-15 medications 
16-20 medications 
21 medications and more 
Total # of patients 
  
1845 
 
21.1 
17 
12.8 
1 
46 
45 
 
6 (7.2%) 
30 (43.5%) 
17 (24.6%) 
9 (13.0%) 
7 (10.1%) 
69 
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Table 3: Episode of Illness Characteristics Continued 
Characteristics  Central Tendency & 
Dispersion/ Type  
Frequency (%)8 
Description of 
Medications 
Diuretics 
Anticoagulants 
Beta-blockers 
Statins 
Non-opioid pain relievers 
Anti-inflammatory 
Antiarrhythmic 
Hypertension 
Opioid pain relievers 
Vitamins 
Antidepressants 
Diabetes medication 
Medication for angina 
Thyroid replacement hormones 
Gastrointestinal 
Corticosteroids 
123 (6.6%) 
116 (6.2%) 
80 (4.4%) 
69 (3.7%) 
69 (3.7%) 
54 (3.0%) 
45 (2.4%) 
37 (2.1%) 
28 (1.8%) 
26 (1.7%) 
25 (1.4%) 
24 (1.3%) 
24 (1.3%) 
24 (1.3%) 
18 (1.0%) 
16 (0.9%) 
 
Distribution of 
Investigations 
  
0 investigation  
1 investigation  
  
33 (19.6%)  
10 (6.0%)  
 2 investigations  
3 investigations  
8 (4.8%) 
  24 (14.3%) 
  
4 investigations or more 
 Total # of investigations 
 
 Mean 
93 (55.4%) 
168 
 
4.0 
 Median 
Std. Deviation 
Minimum 
Maximum 
Range 
 
0 investigation 
1 investigation 
2 investigations 
3-6 investigations 
7 investigations or more 
Total # of patients 
3.99 
0.00 
0 
12 
0 
 
33 (47.8%) 
10 (14.5%) 
4 (5.8%) 
16 (23.2%) 
6 (8.7%) 
69 
    
                                                          
8 The percentage of “description” is the number of episodes of illness with a medication from the total episode of illness sample. It may not add 
up to 100% as some episodes of illness have a few medications whereas others have none. 
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 Table 3: Episode of Illness Characteristics Continued 
 
Characteristics  Central Tendency & 
Dispersion / Type 
Frequency (%)9 
  
Distribution of 
Investigations  
  
Percentile 25 
Percentile 50 
Percentile 75 
 
XR (different body parts) 
ECG 
US (different body parts) 
XR (chest) 
CT10 (different body parts) 
Nuclear Medicine 
 
 
1 referral 
2 referrals 
3 referrals 
4 referrals 
6 referrals or more 
Total # of referrals 
 
0 referral 
1 referral 
2 referrals 
3-6 referrals 
13 referrals or more 
Total # of patients 
 
 
1.0 
4.0 
8.0 
 
43 (25.8%) 
25 (14.9%) 
22 (13.2%) 
19 (11.3%) 
8 (4.8%) 
4 (2.4%) 
 
 
2.0 (1.9%) 
14 (13.2%) 
9.0 (8.5%) 
12.0 (11.3%) 
69.0 (65.1%) 
106 
 
32 (46.4%) 
21 (30.4%) 
6 (8.7%) 
7 (10.1%) 
3 (4.3%) 
69 
 
 
Description of Top 6 
Investigations 
 
 
 
 
 
 
Distribution of Referrals 
  
Description of Top 6 
Referrals 
 
 
 
 
 
 
 
 
Internal Medicine 
Orthopedic Surgery 
Vascular Surgery 
Dermatology 
Cardiology 
Neurology 
 
21 (19.8%) 
12 (11.3%) 
11 (10.4%) 
11 (10.4%) 
6 (5.7%) 
5 (4.7%) 
 
 
                                                          
9 The percentage of “description” is the number of episodes of illness with a referral from the total episode of illness 
sample. It may not add up to 100% as some episodes of illness have a few referrals whereas others have none. 
10 CT computerized tomography (CT-scan) 
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4.3 Objective Two: Comparison of Study Group and Control Group. An 
Independent-Samples T-Test 
A series of independent-samples t-tests were conducted to compare the mean 
values for the number of physician visits, the episode length, the number of medications, 
diagnostic investigations and referrals between the AF and comparison groups.  
We first ran a Levene’s test for equality of variances to assess whether the 
population variances for the groups were equal185. This test result also determined that the 
t–value under no assumption of equal variances was the correct one to use for further 
interpretation of the five dependent variables of interest.  
The review conducted by Glass, Peckham, and Sanders in 1972186 defined an F-
statistic to be robust against heterogeneous variances when groups are equal in size. 
Stevens185 goes further by stating that the robustness of the F-statistic is preserved with 
approximately equal group sizes, i. e., the ratio of the largest sample to the smallest is not 
more than 1.5. This rule of thumb demonstrates robustness again unequal population 
variances only for two out of five dependent variables – for the number of physician 
visits (1487/1287 = 1.2) and for the number of medications (1845/1327 = 1.4). For the 
remaining three variables – the episode length, the number of diagnostic investigations 
and referrals – the ratio values are much higher, thus demonstrating sharply unequal 
sample sizes: 3.7 (1327/361), 7.9 (1327/168), and 12.5 (1327/106), respectively.  
Since the level of significance for Levene’s test is P < .05, the observed variances 
for the two groups are different. Therefore, the assumption of homogeneity of variance is 
violated. It indicates that the two samples for the AF and the comparison groups are not 
taken from populations of equal variances. As a result, the P-value from the first, “equal 
variances assumed” row is not trustworthy: the two groups are substantially unequal in 
size and the population variances are different. 
IBM SPSS accounts for the homogeneity of variance violation by giving slightly 
different results in the second row under “equal variances not assumed”. In fact, when 
performing a standard independent-samples t-test, this software automatically runs a 
Welch t-test statistic under the “equal variances not assumed” or second row.  
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The Welch t-test, also known as the Unequal Variance t-test or Separate Variances 
t-test is used here as an alternative statistic. Since the Welch t-test is robust to unequal 
variances and unequal sample sizes simultaneously, its use is relevant in our case. The 
null hypothesis it tests is that two means are equal even when the variances are 
statistically significantly different from each other as well as when sample sizes are 
unequal. 
To ensure a higher level of robustness to unequal variances and unequal sample 
sizes, the Brown-Forsythe test was also performed. It is arguably even more robust than 
the Welch t-test187. The results of the Welch t-test and the Brown-Forsythe test are 
presented in the table below: the independent-samples t-test under the 'equal variances 
not assumed’ option is in fact the Welch t-test itself. For the five dependent variables of 
interest, the Welch t-test and the Brown-Forsythe test yielded exactly the same results 
within each dependent – group variable pair. 
 The results of independent-samples t-tests are presented below. 
Since for all the dependent variables, the value of significance (Sig.) in Levene’s 
test for the Equality of Variances is below the required cut-off of .05, we interpret an 
alternative t-value generated by the software which is, in fact, the result of the Welch t-
test. As previously mentioned, the Welch test compensates for unequal variances and, for 
result interpretation, the t-value under the ‘equal variances not assumed’ option is 
reported. This applies to the t-test results for all the dependent variables. 
Number of Physician Visits: An independent samples t-test was conducted to 
compare the number of physician visits for the AF and the comparison groups. There is a 
highly statistically significant difference (t (2562.46) = 32.68, P (two-tailed) < .001) in 
the number of physician visits between the two groups, with the mean value for the AF 
group (M = 33.17, SD = 19.04) being over twice that of the comparison group (M = 
13.58, SD = 12.19). Patients with undiagnosed AF visit their primary care physicians, on 
average, 33 times before they obtain a firstly established diagnosis of AF. It usually takes 
patients with other prevalent chronic conditions 2.5 times fewer visits (about 13 in total) 
to visit their family doctor’s offices before their chronic condition is first diagnosed. 
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The Number of Medications: In accordance with the results of the independent-
samples t-test, the difference in the mean number of medications for the AF and the 
comparison groups is highly statistically significant: t (3131.41) = 19.11, P < .001. The 
mean number of different medication names for both groups indicate that AF patients 
tend to have slightly over 50% more medications prescribed (M = 21.13, SD = 12.83), 
when compared to patients with other chronic conditions (M = 13.27, SD = 10.31). 
The Episode Length (Days to Diagnosis): The performed independent-samples t-
test indicates that – in terms of the time-to-diagnosis (number of days) ˗ patients who are 
first diagnosed with AF, wait, on average, for 2.8 years (when the number of days is 
converted to the number of years: 1019.27 days are equal to 2.8 years). Their 
counterparts from the control group, on the other hand, have their new diagnosis of a 
chronic condition established in slightly less than a year and a half (560.17 days). The t-
test findings of t (521.761) = 20.23 are highly statistically significant as the P-value is 
less than .001. In a summary, there is a highly statistically significant difference in the 
time-to-diagnosis for the AF group (M = 1019.27, SD = 391.78) and for the comparison 
group (M = 560.17, SD = 345.16); t (521.761) = 20.23, P (two-tailed) < .001. 
The Number of Investigations: Generally, patients with AF have more diagnostic 
investigations ordered by their physicians compared to the numbers from the comparison 
group. The mean value of 4.88 (standard deviation of 3.99) for the AF group are 50% 
higher than the mean value of 3.28 (standard deviation of 3.72) for the comparison group. 
As is the case with other, previously described dependent variables, this t-test also yields 
a highly statistically significant result (t (205.319) = 4.92) as the two-tailed P-value of the 
test is much lower than the required cut-off of .05 (P < .001). 
The Number of Referrals: An independent samples t-test was performed to 
compare the number of referrals made for the AF and the comparison groups. There is a 
highly statistically significant difference (t (1326.000) = 4.90, P (two-tailed) < .001) in 
the number of referrals made between the two groups, with the mean value of 1.0000 and 
the standard deviation of 0.7713 for the AF group being, however, very close in its 
numeric value to the mean of  0.7769 and the standard deviation of 1.65819 for the 
comparison group. 
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Table 4: Group Statistics for Independent-Samples T-Test 
Characteristic Group N Mean Std. Deviation Std. Error Mean 
 
Physician Visits 
 
AF 
 
1487 
 
33.1742 
 
19.04291 
. 
49383 
Comparison 1287 13.5835 12.18994 .33979 
     
Medications AF 1845 21.1301 12.82827 .29865 
Comparison 1327 13.2683 10.30817 .28297 
     
Episode Length (Days to 
Diagnosis) 
AF 361 1019.27 391.782 20.620 
Comparison 1327 560.17 345.160 9.475 
     
Diagnostic Investigations AF 168 4.8750 3.99429 .30817 
Comparison 1327 3.2781 3.71723 .10204 
     
Referrals AF 106 1.2347 .7713 .00103 
Comparison 1327 .7769 1.65819 0.04552 
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Table 5: Independent-Samples T-Test 
 
 
 
 
Characteristic 
 
 
 
Assumption 
Levene’s Test for 
Equality of 
Variances 
 
T-Test for Equality of Means 
 
 
F 
 
 
Sig. 
 
 
t 
 
 
df 
 
Sig. 
(2-tailed) 
 
Mean 
Difference 
 
Sd. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
 
 
Physician 
Visits 
Equal variances 
assumed 
 
369.067 .000 31.709 
 
 
32.682 
2772 .000 
 
 
.000 
19.59065 
 
 
19.59065 
.61782 
 
 
.59944 
18.37921 
 
 
18.41522 
20.80208 
 
 
20.76608 Equal variances 
not assumed 
  2562.461 
 
 
Medications 
Equal variances 
assumed 
 
Equal variances 
not assumed 
 
122.153 .000 18.448 
 
 
19.109 
3170 
 
 
3131.407 
.000 
 
 
.000 
7.86181 
 
 
7.86181 
.42616 
 
 
.41142 
7.02624 
 
 
7.05512 
8.69738 
 
 
8.66849 
 
 
Episode 
Length (Days 
to Diagnosis) 
 
Equal variances 
assumed 
 
Equal variances 
not assumed 
 
26.217 .000 21.748 
 
 
20.231 
1686 
 
 
521.761 
.000 
 
 
.000 
459.100 
 
 
459.100 
 
21.110 
 
 
22.693 
417.695 
 
 
414.519 
500.505 
 
 
503.680 
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Table 5: Independent-Samples T-Test Continued 
 
 
 
 
Characteristic 
 
 
 
Assumption 
Levene’s Test for 
Equality of 
Variances 
 
T-Test for Equality of Means 
 
 
F 
 
 
Sig. 
 
 
t 
 
 
df 
 
Sig. 
(2-tailed) 
 
Mean 
Difference 
 
Sd. Error 
Difference 
95% Confidence 
Interval of the 
Difference 
Lower Upper 
Diagnostic 
Investigations 
+ 90-Day Lag 
Period after 
Diagnosis 
Equal variances 
assumed 
 
10.282 .001 5.201 
 
 
32.682 
1493 .000 
 
 
.000 
1.59693 
 
 
1.59693 
 
30702 
 
 
32462 
.99468 
 
 
.95691 
2.19917 
 
 
2.23695 Equal variances 
not assumed 
  2562.461 
Referrals + 90-
Day Lag 
Period after 
Diagnosis 
Equal variances 
assumed 
 
Equal variances 
not assumed 
 
51.156 .000 1.385 
 
 
4.900 
1431 
 
 
1326.000 
.166 
 
 
.000 
.22306 
 
 
.22306 
 
.16111 
 
 
.04552 
-.09298 
 
 
.13376 
.53910 
 
 
.31236 
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Table 6: Comparison of Standard One-Way ANOVA and Independent-Samples T-Test (under ‘Equal Variances Assumed’) 
Results 
 
 
Note: 
√ANOVA F-value = t-value for independent-samples t-test (under ‘equal variances assumed’) 
 
 
Type of Test 
 
 
F/t-Statistic Sig. 
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D
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g
n
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ic
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v
es
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g
a
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o
n
s 
 
R
ef
er
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ls
 
 
Standard One-
Way ANOVA 
Test 
 
 
1005.477 
 
 
340.336 
 
 
472.963 
 
 
27.054 
 
 
1.917 
 
 
.000 
 
 
.000 
 
 
 .000 
 
 
.000 
 
 
.166 
   
 
Independent-
Samples T-
Test (under 
'equal 
variances 
assumed’) 
 
 
 
 
31.709 
 
 
 
18.448 
 
 
 
21.748 
 
 
 
5.201 
 
 
 
1.385 
 
 
 
.000 
 
 
 
.000 
 
 
 
.000 
 
 
 
.000 
 
 
 
.166 
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Table 7: Comparison of Robust Tests of Equality of Means and Independent-Samples T-Test (under ‘Equal Variances Not 
Assumed’) Results 
 
 
 
Type of Test 
 
 
F/t-Statistic Sig. 
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Welch T-Test 
 
1068.091 
 
365.147 
 
409.293 
 
24.200 
 
24.01 
 
 
 
 
.000 
 
.000 
 
.000 
 
.000 
 
.000 
   
 
Brown-
Forsythe Test 
 
 
1068.091 
 
365.147 
 
409.293 
 
24.200 
 
24.01 
 
.000 
 
.000 
 
.000 
 
.000 
 
.000 
 
Independent-
Samples T-
Test (under 
'equal 
variances not 
assumed’) 
 
 
 
 
32.682 
 
 
 
19.109 
 
 
 
20.231 
 
 
 
4.919 
 
 
 
4.900 
 
 
 
.000 
 
 
 
.000 
 
 
 
.000 
 
 
 
.000 
 
 
 
.000 
Note: 
√Welch t-test asymptotically F-distributed value = √Brown-Forsythe test asymptotically F-distributed value = t-value for independent-
samples t-test (under ‘equal variances not assumed’) 
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4.4 Objective Two: Magnitude of Effect. Effect Size Analysis. 
Based on the findings across the four different effect size measures, the highest 
level of consistency in the reported effect magnitude is demonstrated by the statistics that 
rely on standard deviation units to present the difference between the two groups, i. e., 
Cohen’s d, Hedge’s g, and Glass’ delta. Not a single statistic of the three above indicates 
a small size of effect for any of the five dependent variables.  
The results of the eta squared, on the contrary, are indicative of a borderline 
small/medium effect size (10%) for the number of medications prescribed and a very 
small magnitude of effect for the diagnostic investigations ordered (only 2%). When the 
eta squared findings for these two variables are compared to other effect size statistics, 
the magnitude of the differences in the means is substantially higher, presenting a three-
level paradigm of effects. Specifically, the range of effect includes: 1) the medium effect 
in Cohen’s d statistic for the diagnostic investigation variable; 2) the medium magnitude 
of effect in Glass’ delta and Hedge’s g statistics for the medication and diagnostic 
investigation variables, and 3) the borderline medium/large effect for the medication 
variable in Cohen’s d statistic.  
The results of effect size statistics are presented in Table 7. They are interpreted 
entirely from a quantitative perspective, without any account of their practical relevance 
and clinical significance in the context of an AF patient’s journey.  
 The Number of Physician Visits: The value of 0.27 or 27% of variance in eta 
squared statistic is indicative of the large size of an effect by the group assignment. In 
other words, 27 per cent of the total variation in the number of physician visits depends 
on which group the patient is assigned to. Apart from the statistically significant 
difference between the two groups, the measured effect index of 0.27 gives practical 
importance to the finding. 
The value of Cohen’s d = 1.23 indicates that the difference between the mean 
number of physician visits in the AF group and the comparison group is larger than one 
standard deviation, to be more precise, larger than 1.23 SD (large effect). Similarly, in 
Hedge’s g and in Glass’ delta statistics, the magnitude of difference is larger than one 
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standard deviation: 1.21 SD in Hedge’s g, 1.03 SD in Glass’ delta1, and 1.61 SD in 
Glass’ delta2. Overall, for the number of physician visits as a dependent variable, the 
effect size indices are consistent in the magnitude of effect being reported as large across 
all of them.  
The Number of Medications: For the medication variable, some degree of 
inconsistency across the four effect size indices is observed. The eta squared value of 
0.10 measures the 10 per cent proportion of variance in the number of medications that is 
explained by the group assignment. Purely in quantitative terms, it is a borderline 
small/medium size of an effect. At the opposite end of the spectrum is the value of 0.68 
in Cohen’s d statistic that implies a borderline medium/large effect size. In the middle are 
the values of Hedge’s g (0.66) and Glass’ delta statistics (0.61 and 0.76 for Glass’ delta1 
and Glass’ delta2, respectively), with the reported medium magnitude of effect for both 
indices. 
The Episode Length (Days to Diagnosis): For the episode length variable, the 
mean values for the two groups differ by 1.24 (Cohen’s d statistic), 1.29 (Hedge’s g 
statistic), and by 1.17 and 1.33 (Glass’ delta1 and Glass’ delta2, respectively) standard 
deviations. The eta square value of 0.22 (or 22%) is also highly suggestive of a large 
effect size: the 22% proportion of variance in the episode length is due to the group 
variable. The magnitude of effect is consistent throughout the four effect size indices. 
Such results suggest that the length of an episode of illness varies substantially for a 
patient depending on one’s group allocation.  
The Number of Investigations: When applying the SD-based effect size measures, 
i.e., Cohen’s d, Hedge’s g, and Glass’ delta, the effect size for the investigation variable 
can be interpreted as medium. Only the eta square value of 0.02 (or 2%) indicates a small 
association of variance in the number of investigations with the group allocation.  
The Number of Referrals: As already mentioned, patients with chronic conditions 
and co-morbidities are not often referred to specialty outpatient facilities for diagnosis. 
Being referred to as “complex care physicians”, primary care physicians are heavily 
relied on in terms of management of patients with high-cost chronic conditions.182 As a 
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result, the allocation of a patient to an AF or a comparison group does not make much of 
a variation as far as the diagnostic referrals are concerned. This status quo is reflected in 
the low values of the effect size statistics (the eta square value of 0.001 or 0.1%; the 
Cohen’s d value of 0.35; the Hedge’s g value of 0.28, and the Glass’ delta values of 0.59 
and 0.13, respectively), thus indicating a very small effect size. Despite its high statistical 
significance of the independent samples t-test, the difference between the two groups in 
the number of referrals is although not trivial, but still very small.  
By their original definition, our dependent variables have meaningful metrics that 
are expressed by the number of physician visits, medications, referrals, diagnostic 
investigations and days-to-diagnosis. These metrics are practically significant and 
directly interpretable188 which is a great asset. However, IMB SPSS – like any other 
statistical software – standardizes effect sizes. As a result, the original meaningful scale 
of metrics is lost but standardized effect sizes (in this case, the proportion of variance in 
percentage for the eta square statistic and standard deviation units for Cohen’s d, Hedge’s 
g and Glass’ delta) are directly comparable across studies with different-scale 
outcomes188. 
The goal is ˗ despite the statistically significant differences between the AF and 
the comparison groups in relation to the set of the dependent variables ˗ to quantify the 
magnitude of those differences. In this sense, as rightfully stressed by Kline,188 the size of 
an effect is a statistic “with a purpose of quantifying a phenomenon of interest”. The 
rejection of a null hypothesis, by itself, does not guarantee substantive significance. 
Kline180insists that clearly explicating the importance of the research findings in terms of 
their clinical relevance and practical value for the patients is required.  
The decision to use multiple effect size indices is a direct consequence of the 
dilemma on how “to improve the communication of the results”188. The literature allows 
reporting of multiple effect sizes that directly address the same research question to test 
for the consistency of the effect size results. The choice of the effect size statistics is also 
informed by the literature and is based on their commonality and relevance to the field of 
research. D and r statistics have been chosen, with the d statistics describing mean 
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contrasts in units of standard deviation and r statistic being a proportion of variance 
explained effect size.188 
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Table 8: Summary of Effect Size Calculations 
Dependent 
Variable 
Independent 
(Group) 
Variable 
Sample 
Size (N) 
Mean SD Sig. (2-
tailed) 
Eta 
squared 
(η 2) 
Cohen’s 
d 
Hedge’s 
g 
Glass’ 
delta1 
(1) 
Glass’ 
delta2 
(2) 
 
Physician 
Visit 
AF Group 1487 33.1742 19.04291  
 
 
<0.001 
 
 
 
0.27 
large 
 
 
1.225344 
(1.23) 
large 
 
 
1.207246 
(1.21) 
large 
 
 
1.0287661 
(1.03) 
large 
 
 
1.6071203 
(1.61) 
large 
Comparison 
Group 
1287 13.5835 12.18994 
 
Medication 
AF Group 1845 21.1301 12.82827  
 
 
<0.001 
 
 
 
0.10 
small/me-
dium 
 
 
0.675607 
(0.68) 
medium/ 
large 
 
 
0.664028 
(0.66) 
medium 
 
 
0.6128496 
(0.61) 
medium 
 
 
0.7626766 
(0.76) 
medium 
Comparison 
Group 
1327 13.2683 10.30817 
 
 
Episode 
Length 
(Days to 
Diagnosis) 
AF Group 361 1019.27 391.782  
 
 
<0.001 
 
 
 
0.22 
large 
 
 
1.243474 
(1.24) 
large 
 
 
1.290954 
(1.29) 
large 
 
 
1.1718251 
(1.17) 
large 
 
 
1.3301078 
(1.33) 
large 
Comparison 
Group 
1327 560.17 345.160 
 
Diagnostic 
Investigation 
+ 90-day Lag 
Period after 
Diagnosis 
AF Group 168 4.8750 3.99429  
 
 
<0.001 
 
 
 
0.02  
very small 
 
 
0.413893 
(0.41) 
medium 
 
 
0.425927 
(0.43) 
medium 
 
 
0.3997957 
(0.40) 
medium 
 
 
0.4295941 
(0.43) 
medium 
Comparison 
Group 
1327 3.2781 3.71723 
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Table 8: Summary of Effect Size Calculations Continued 
Dependent 
Variable 
Independent 
(Group) 
Variable 
Sample 
Size (N) 
Mean SD Sig. (2-
tailed) 
Eta 
squared 
(η 2) 
Cohen’s 
d 
Hedge’s 
g 
Glass’ 
delta1 
(1) 
Glass’ 
delta2 
(2) 
 
Referrals + 
90-day Lag 
Period after 
Diagnosis 
AF Group 106 1.0000 .00000  
 
 
<0.001 
 
 
 
0.001 
(almost no 
effect) 
 
 
0.354018 
(0.35) 
small 
 
 
0.284381 
(0.28) 
small 
 
 
0.5935433 
(0.59) 
medium 
 
 
0.1345443 
(0.13) 
small 
Comparison 
Group 
1327 .7769 1.65819 
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   CHAPTER FIVE – DISCUSSION AND CONCLUSION 
 
5.1 Strengths of Research 
To the best of our knowledge, this has been one of the first studies to describe an 
episode of AF illness in terms of the number of physician visits, the episode length, the 
diagnostic investigations ordered, the medications prescribed, and the referrals made in a 
primary care setting. The literature review did not identify any studies that are related to 
the diagnosis of AF in the conceptual framework of an episode of care. Not only were 
there no AF studies that would operationalize the episode of care as an appropriate unit 
of assessment161, but also no current research explored time-to-diagnosis characteristics 
in AF on a visit-per-visit basis. Using high-quality electronic medical records as a data 
source for describing an AF episode of illness is another innovation. Given the rising 
popularity of electronic health records systems and a profound shift of medical record 
keeping from paper-based physicians’ notes to computerized modules, the methodology 
employed in this research is transferable for use in other types of medical practice and 
medical conditions. 
The current research also contributes to quantitative research conducted from the 
perspective of a patient rather than a health care provider. Choosing patient-important 
outcomes helps to meaningfully map the patient’s journey to the diagnosis of AF in 
quantitative terms.  Previous research on other chronic conditions explored conditions of 
interest within an episode of care. The focus of this study, however, is on an episode of 
illness that should be clearly distinguished from both an episode of disease and an 
episode of care.  
In order to capture the patient’s experience in navigating the Canadian health care 
system with the ultimate goal of diagnosis establishment, this research has a look-back 
period of up to 4 years and specifies a distinct end-point. Such an approach of including 
complete episodes of illness allows to explore patterns of health care utilization in AF 
diagnosis. The research results can be of interest to different stakeholders ˗ patients, 
physicians, policy makers and governmental agencies – as they identified the gaps in the 
diagnosis of a chronic condition that can be addressed in future research.  
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In the modern context, general practice is a complex care entity that is heavily 
relied on for diagnosis and management of high-cost chronic conditions. That is why 
recognizing patients’ challenges, identifying gaps on an upstream, system level and 
facilitating positive downstream changes as well as stimulating a shift in professional 
culture are key.  
 
5.2 Limitations of Research 
A major limitation of this research is the source of data itself. Electronic medical 
records (EMRs) were developed to collect data for the purpose of individual patient 
care, not for the purpose of research. As a result, the same type of information can be 
stored in multiple places in the database. A number of terms can be used to denote the 
same condition or phenomenon. In such a case, the researcher develops a list of related 
terms and verifies it for completeness by examining each description to ensure that no 
related terms are omitted. At the same time, clinically irrelevant – yet valuable for 
research – information may not be found in EMRs. In an attempt to locate, extract and 
analyze data, researchers have to explore all possible locations in an electronic medical 
record which might not be feasible. 
The dependent variables that were used imply some degree of uncertainty in data 
interpretation. For instance, a patient may or may not express all the reasons for 
encounter in the form of symptoms, complaints and requests for medical procedures. 
This is particularly true now when patients are asked to restrict their encounter with a 
physician to one major concern. The physician, on the other hand, is an initial recipient 
of the patient’s information who exercises judgments on what to record in the database, 
based entirely on situated and fragmented pieces of information189. This may or may not 
lead to depiction of complete patient information. The question remains open how 
concordant the patient self-report and the medical record are.  
Another important limitation of this research that is beyond control is a lack of 
definitive, proven information on the variables of interest: the number of physician 
visits, the medications prescribed, the diagnostic investigations ordered and the referrals 
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made. Hoping to meet current clinical guidelines, family doctors record is what 
recommended or prescribed to patients. The actual result of a physician-patient 
encounter remains unknown. It does not necessarily translate into the patient’s 
compliance to the treatment protocol. Other external factors such as long wait lists for a 
specialty outpatient service (in case of referrals) may cause patient non-compliance. A 
patient is prescribed a medication but whether the prescription is filled is not known. 
Similarly, a diagnostic investigation is ordered for a patient but there are no readily 
available means of confirming that the investigation was conducted.  
The logical consequence of the two previous points ˗ the “uncertain” and 
“unknown” nature of medical data - is its incompleteness. The researcher cannot be sure 
if the data are missing as such (in terms of medications, referrals and investigations) due 
to the physician’s failure to record them or whether there have been truly no referrals 
made, no diagnostic investigations ordered, and no medications prescribed.  
Finally, we cannot establish a distinct start point of an episode of illness due to 
transiency of symptoms in AF. That is why the decision has been made (and justified in 
more detail in the Methods chapter) to use all of the available look-back period when 
determining the boundaries of an episode of AF illness.  This may overestimate the 
duration of AF if the presenting symptom was not AF-related and AF first occurred at a 
later date. 
 
5.3 Objective One: Characteristics of an Atrial Fibrillation Episode of Illness 
 
5.3.1 Number of Physician Visits 
As already mentioned, no literature on characterizing an episode of AF illness in 
the context of the dependent variables used in this thesis has been identified. With AF 
being a chronic condition, we decided to compare our findings with the reported results 
of the studies on other chronic conditions in family practice. Since the comparison group 
consists of patients with the nine most common chronic conditions, the search was 
extended to include any relevant information on those nine conditions. 
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As is evident from the published research on the 14 highest-cost chronic 
conditions in the USA182, a majority of patients seek care for their chronic conditions 
from a generalist (69%) rather than a specialist physician (24%). 
 It is increasingly recognized that primary care medicine is distinctly different 
with regard to pathologies, patients, and clinical presentations general practitioners deal 
with in comparison with their specialty outpatient colleagues. The populations in general 
practice are relatively unselected190. Rigid diagnostic labelling is less important than 
deciding on an appropriate course of action. For instance, the use of a specific diagnosis 
can be simply a justification of antibiotic treatment instead of its reason191. The so-called 
diagnostic uncertainty is not the new Achilles’ heel of general practice, as 
metaphorically labelled by Howie in 1972191, but rather an inherent, salient feature of a 
primary care setting192. Often, family physicians frame their diagnostic decisions in 
dichotomous terms: referral versus non-referral, diagnostic investigation versus no 
diagnostic investigation, and treatment versus non-treatment.  
The current research yields some insights with reference to the number of in-
office physician visits between the AF and comparison groups. Patients awaiting the 
diagnosis of AF have, on average, 2.5 times more visits than patients with other 
undiagnosed chronic conditions. In the context of family practice, it is still unclear why 
this happens. 
There are a number of possible explanations for the observed difference in the 
number of physician visits between the two groups. A plausible explanation would be 
the asymptomatic and transient nature of symptoms in AF. It takes time for the disease 
to declare itself in the form of signs and symptoms. Or, on the contrary, the diagnosis of 
AF is established incidentally with no related reason for encounter recorded in the 
EMRs when the patient is completely asymptomatic. Another possible explanation is the 
presence of multi-morbidity that clouds the clinical picture.192 When comparing the two 
groups in the current work in terms of other chronic conditions  , we can explain the 
substantive difference in the number of physician visits due to the older age of the AF 
group with a larger number of associated chronic conditions. These differences are 
presented by both statistically significant t-test results and by a large effect size. 
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5.3.2 Episode Length 
The dependent variable of the episode length is directly connected to the number 
of physician visits. It is also associated with the visit continuity on patients’ experience 
with care193. It would be valuable to understand whether visit continuity is beneficial to  
AF patients. 
Little do we know about the realized and potential wait time to diagnosis. In a 
situation when the patient does not present with any observable signs and reports no 
symptoms, there is technically no wait time to diagnosis. The biggest obstacle in 
“recognizing the zebras among the horses” is inability to rigidly define a starting point 
of an AF episode of illness that would be measurable and expressed in standardized 
terms. Even developing typical scenarios or patterns of diagnostic steps is problematic. 
As McWhinney has pointed out, in the situated, community-based context, the focus of a 
primary care physician is on patient management and not so much on diagnosis 
establishment190. 
The key defining feature of general practice is its holistic approach towards 
disease and illness194. The patient’s journey to diagnosis is intertwined with the context 
of an individual’s life experience and circumstances, including a myriad of diverse, 
hardly quantitatively measurable factors such as social, environmental, occupational, 
developmental, etc. Manipulations and tools of any sort (physical examination, 
diagnostic testing, referrals) are only assistive devices for a family doctor to define a 
“whole person diagnosis” of patient problems195 from a biopsychosocial perspective. 
The question is, however, whether early diagnosis and intervention may 
favourably impact the prognosis38. AF is recognized as a progressive disease that 
generally evolves from paroxysmal through persistent to “permanent” forms38. 
Theoretically, earlier diagnosis and timely intervention might limit or prevent the 
disease progression. Furthermore, a personalized approach to the disease management 
entails a treatment plan that is tailored to an individual’s risk factors, pathophysiology, 
and genetic predisposition196. Nattel et al.38 believe that earlier diagnosis and treatment 
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of AF can also prevent serious long-term complications such as blood clot formation, 
stroke, heart attack, heart failure, and sudden cardiac arrest.  
Clinical efficacy of early therapy warrants confirmation. If it can be shown that 
more proactive diagnosis and treatment prevent progression and complications of AF, 
intensive ECG monitoring could be established as a clinically relevant screening tool.  
 
5.3.3 Medication 
Based on our findings, medications are prescribed for the AF group of patients, 
with a mean of 21.1 and standard deviation of 12.8. When compared to the control 
group, AF patients tend to get by 50% more medications than the individuals living with 
other chronic conditions (mean of 13.27 and standard deviation of 10.31). 
Our findings are consistent with some previous studies. Of particular interest are 
the results of the 2008 Commonwealth Fund International Health Policy Survey 
conducted among eight industrialized nations: the United Kingdom, Canada, the United 
States, Australia, New Zealand, Germany, France, and the Netherlands172. This survey 
builds on an annual series that informs government health policies in the surveyed 
countries. This international study focused on experiences of chronically ill patients with 
complex health care needs. Among the major inclusion criteria were presence of chronic 
disease(s) and  frequent contact with the health care delivery system, including 
hospitalizations and major surgeries within the last two years. The AF patients took six 
or more prescription medications regularly whereas 30-50% per cent of the international 
cohort of the participants reported taking four or more medications.  
These findings are expected as they reflect the high dependency of chronic 
patients on medication for disease management. In spite of the complicated medication 
regimens, approximately 40% of the respondents were concerned by a lack of medical 
supervision when neither primary care physicians, nor pharmacists reviewed their 
medication lists172. 
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5.3.4 Investigation 
The most common type of diagnostic investigations was an X-ray of different 
body parts. ECG comprised a relatively small proportion (less than 15%) of the total 
number of investigations. Among other utilized diagnostic investigations were 
ultrasound and computerized tomography scans of different body parts.  
These findings resonate with characteristics of a family practice model that are 
commonly described in the literature. For instance, primary care physicians are 
estimated to diagnose a conventional disease in approximately 50% of patients 
presenting to their offices197. In another study, after a 6-month follow-up period, only 
50% of the patients with chest pain were told the cause of their disease198. The numbers 
were even lower in another study in which only 20% of ambulatory male patients with 
abdominal pain were ascribed a definitive diagnosis199. 
Apparently, within the framework of family practice that “includes primary, 
comprehensive, continuing, community-based, patient-centred, and preventive care”, 
diagnostic investigations are useful in a small proportion of 5% of cases200. 
As becomes clear from the above mentioned examples, although a part of family 
practice, radiological and laboratory investigations have a limited role, leading to the 
diagnosis establishment in 2-3 cases of every hundred of patients.  
The general tendency that can be easily observed by a patient visiting one’s 
physician’s office or even an emergency department in hospital is a selective use of 
diagnostic testing for the sake of avoiding diagnostic inefficiency, i. e., unnecessary, 
excessive testing, and over-diagnosis. In fact, over-diagnosis can have very similar 
untoward consequences as under-diagnosis does. A striking example comes from the 
study on diagnosing organic heart disease in children: false positive cases demonstrate 
as much deterioration in social and physical function as children who do have the 
disease201. 
 
5.4 Objective Two: Effect Size in Study Group and Comparison Group 
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In terms of the effect size, it is important to consider not only the magnitude for 
each variable of interest but also the clinical relevance and practical value. Per se, a 
“small” or “medium” clinically relevant effect size is more important than a “large” 
effect of less practical value. It is more so a context-dependent judgment call. 
We are aware of criticisms of so-called “T-shirt effect sizes”202 when standardized 
magnitudes of effect are arbitrarily labelled as “small”, medium”, and “large” and applied 
with little considerations of a particular context. Not withstanding the context-dependent 
aspect of the effect magnitude, we purposively interpret effects with the rigor of 
significance testing. It is an experimental, purely quantitative type of research, and 
contextual analysis is outside its realm of expertise. Cohen203 suggested threshold values 
of effect magnitude in behavioral research as a general rule of thumb rather than a ready-
to-use recipe. These values are arbitrary and should not be interpreted rigidly204.  No 
existing related literature on the effects of our variables of interest in a primary care 
setting has been identified. Therefore, we cannot interpret our effects in explicit or direct 
comparison against the published effects, as recommended by Thompson204.  
 
5.5 Generalizability of Results 
5.5.1 Representativeness of DELPHI Population in Comparison to General 
Practice Population 
In spite of a relatively small sample of AF cases, the DELPHI database is largely 
representative of Ontario general practice patients and therefore, the results being 
generalizable to a Canadian primary care setting. Below is the comparison of prevalence 
of such patient-important outcomes as AF and stroke between the DELPHI database and 
the current literature. The DELPHI descriptive statistics presented in Appendix K is 
consistent with the age and sex distribution of AF patients and prevalence of AF by age 
group in the general population. 
As a recognized independent risk factor for stroke, AF accounts for at least a 5-
time increase in its incidence.205, 2,206, 207 Overall, the literature suggested 2-3% per year 
of an absolute risk of stroke in the adult population versus 10-12% risk in patients with a 
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previous cerebrovascular accident.208 Thus, 679 out of 48096 patients with stroke were 
identified in the DELPHI database that corresponds to 1.4%. Among 1500 patients with 
AF in the DELPHI database (Appendix K), 140 of them (9.3%) had a stroke: 62 females 
and 78 males.  
The ten-year prevalence of AF in the DELPHI database is 3.1% that rose steadily 
with age up to the 80-89 age group (Appendix K). The majority of large studies 
conducted in North America and Europe reported a prevalence of 0.4% to 3.9%. 
Notably, such variation in the disease prevalence can be explained by a number of 
factors: 1) hospital-based studies209,210 showed higher rates of AF than community-based 
ones; 2) studies conducted in different ethnic populations such as African Americans2, 
211 and Indo-Asians212 and in different geographical areas213, 209, 210 yielded a variety of 
prevalence estimates; 213, 209, 210 3) differences in age stratification as well as inclusion of 
limited age ranges214 can explain considerable variance of AF prevalence.  
To demonstrate DELPHI feasibility in answering a specific research question and 
its representativeness of general practice, the DELPHI prevalence values for AF were 
compared to the ones from large studies across the world that were similar to the 
DELPHI database in crucial parameters.  
The eight-year overall prevalence of AF in the adult population, based on the 
Clalit Heath Services computerized database of 2 420 000 adults (Israel), was 3%. It was 
a methodologically sound study that was conducted in the population older than 20 years 
of age and included both community and hospital diagnoses of AF.  
Another large, population-based study that was conducted in Sweden with similar 
patient populations reported a prevalence of 3.2%. The data were extracted from primary 
healthcare, specialized outpatient, hospital drug registries in a Swedish region with 1.56 
million residents215. 
A study conducted by German researchers aimed at quantifying age- and gender-
specific prevalence of AF in Germany.216 A database covering a large patient population 
of all ages (8.298 million members of two German statutory health insurance funds) was 
analyzed and the reported prevalence was 2.132%. 
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5.5.2 Compatibility of the DELPHI Database with Other Electronic Medical 
Record Databases 
The DELPHI database is designed in the same structure as the nation-wide 
electronic medical record surveillance database called “CPCSSN” (the Canadian Primary 
Care Sentinel Surveillance Network). Therefore, the DELPHI database is fully compatible 
with CPCSSN. The DELPHI database can be used as a pilot test platform of data search 
fields as well as diagnostic and treatment algorithms for a variety of diseases. Following 
initial statistical analyses of DELPHI findings, researchers can shift towards examining 
region-determined commonalities and differences across primary care experience of 
Canadians for a specific disease.  
In its coding major types of structured data ˗ symptoms, diseases, and interventions 
– the DELPHI database is similar to larger UK-located databases, specifically, to the 
General Practice Research Database in the United Kingdom158.  
Although available now in 19 languages, the core of a computer-based patient 
record classified with ICPC is language independent. This allows comparisons of data from 
different countries161. Furthermore, it develops family medicine to a profession with a well-
defined and empirically based framework of reference161, 159. 
Another operational characteristic of the DELPHI database is its inherent capacity 
to monitor preventive care and chronic diseases that is similar to the US databases217, 218. 
The feature that is unique to the DELPHI database is that it makes it possible to pose health 
service-related questions and answer them. The examples of such would be the scope of 
interdisciplinary care, wait times and workload157. 
In order to create a researchable database, regular data quality assessment and 
collaboration with information technology specialists are warranted157. After the DELPHI 
database was populated with extracted data, a data quality assessment system was initiated. 
This ensures that the data are complete and standardized across the participating sites, i. e., 
suitable for research purposes157.  
Given data access by researchers, EMR data have several important advantages for 
research157. First, longitudinal data enable researchers not only to explore a natural course 
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of various diseases that are treated in general practice but also to follow patterns of care 
delivery over time. Second, the DELPHI database is particularly useful in monitoring 
preventive care and chronic disease management. This aspect of usefulness was also 
touched upon in several US studies217, 218. Third, data can be collected, extracted and stored 
relatively quickly. Overall, EMRs are a reliable source of information on various aspects of 
primary health care. 
  
5.5.3 Comparison of ICPC-Coded DELPHI Population and 2016 Canadian 
Census Population 
The comparison of ICPC-coded DELPHI population is made to the 2016 
Canadian Census population. It was a seventh quinquennial census conducted by 
Statistics Canada on May 10, 216. The 2016 Canadian Census presents the most recent 
detailed enumeration of the Canadian residents. It counted a population of 35,151,728 
which was a 5-per cent increase from the 2011 population of 33,476,688. 
When compared to the 2016 Canadian Census population, the DELPHI ICPC-
coded population is generally older and has a slightly higher proportion (by 5%) of 
female patients. In Appendix L, the median age of 54 years in the ICPC-coded DELPHI 
population is higher than the median age of 40 years reported by the 2016 Canadian 
Census219. The proportion of female population in the ICPC-coded DELPHI project is 
by 5% higher (56%) in comparison to the 51% from the 2016 Census.  
The fact that more older females comprise the DELPHI population brings into 
consideration the umbrella term of “the complex older patient” in general practice220. 
This concept includes a number of social, psychological and medical problems221. In 
broad strokes, complex patients, i. e., individuals with a few comorbidities and 
functional disabilities, prefer to live in the community as long as possible rather than 
being placed into residential facilities. This tendency is, in turn, reflected in higher 
numbers of patients with several concurrent problems whom physicians see in their 
practices221.   
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As well documented in previous research220, older individuals and females are 
more likely to be included into clinical samples as they tend to visit their physicians 
more often than the general population. However, this discrepancy in age and sex 
distribution does not indicate that the DELPHI population is different from the Canadian 
population, overall. The reason is that the ICPC-coded DELPHI population represents a 
random sample of patients who seek medical care from their family physicians.  
 
5.6 Policy Implications 
It is increasingly recognized that heath care delivery systems all over the world 
are facing the challenge of aging, chronically ill patients with complex care needs. The 
growing burden of care is falling on primary care physicians. However, the degree to 
which general practitioners are relied on in providing patient-centered care, might be 
neither realistic, nor fully appreciated222. The increasing societal demands and public 
expectations of the quality of medical service can make it impossible for physicians to 
meet all expectations. It is within the realm of family practice to screen patients and 
identify their needs, to offer preventive services and provide education, to work with 
communities and to stimulate behavioral changes182. This list is far from exhaustive. The 
topic being debated within the last few years is whether there is time for managing 
patients with chronic diseases in primary care. Ostbye et al.223 calculated that in order to 
be compliant with current clinical guidelines of managing hypertension and diabetes, a 
physician would need about 10 hours per day to care for each patient with multi-
morbidities. 
This study is a first step towards identifying common areas of overlap in terms of 
factors, barriers and facilitators of the AF patient’s journey towards diagnosis in the 
primary care setting. Developing a detailed, multi-level knowledge transfer plan based 
on consultation, involvement and partnership with key stakeholders - patients, 
caregivers, healthcare providers and multi-disciplined researchers – can facilitate 
positive changes in the current clinical guidelines for diagnosing and managing AF. 
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5.7 Future Research 
Patients’ experiences of arrhythmia diagnosis extend across multiple health care 
sectors. For the majority of them, however, the initial diagnosis and management of AF 
will be conducted in primary care,29 with the family doctor’s office being a starting point 
of a patient’s journey. In Canada, primary care physicians serve as gatekeepers for further 
referrals and diagnostic investigations. The primary care setting continues to be a 
coordinating site of patient care. That is why the focus of this research is on mapping 
patients’ experiences using electronic medical records (EMRs) that are accessed through 
the DELPHI database. The data collected from the physicians’ offices was used to 
describe a patient’s journey in quantitative terms.  
It is quite an endeavor to tell a story behind the numbers when patients’ 
experiences are explored solely quantitatively, with the use of a database. With qualitative 
research, on the contrary, a patient’s journey can be captured and mapped through focus 
groups, surveys and in-depth narrative interviews. Although it is outside the scope of this 
thesis, further qualitative and mixed-methods research is warranted. It can provide 
knowledge of the context by documenting various aspects of a patient’s life between 
interactions with the health care system. Ideally, we would like to know more about the 
life of AF patients between doctor visits. The contextual approach might facilitate more 
meaningful interpretation of patient history records, physician notes and questionnaire 
scores.  
For future research, an overarching goal could be to appreciate patients’ stories 
behind the numbers, hear their voices and acknowledge patients’ right to fully participate in 
the planning and delivery of patient-centered care. To do so, it is important to understand 
what it is like for common Canadians to live with a potentially serious condition and seek 
medical care from their physicians. By assessing similarities and differences across a 
diversity of patients’ experiences, the researcher can potentially inform patient-centered 
care, advocate for quality control initiatives and account for context-level quality of life 
determinants. 
Another important aspect to consider for future research is the socio-economic 
impact of atrial fibrillation on individuals and their families. What we need to further know 
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is an associated public health implication and its various aspects. To name a few, it would 
be valuable to explore opportunity costs for patients and care givers, quality of life 
variables (both physical and psychological), health care system utilization such as doctors’ 
referrals to tertiary care facilities, atrial fibrillation hospitalizations, emergency department 
visits, etc.  
An interesting opportunity within the qualitative realm could be participatory 
action research. Patients with the experience of living with AF engage in the research 
process and provide some insights by thinking critically, yet in a distance from their own 
stories of a patient’s journey to diagnosis. This type of inquiry empowers participants to 
co-manage the research cycle – from its conceptualization to the completion and 
knowledge translation phases. The patient-led research could potentially identify unmet 
needs and concerns as well as define patient-important outcomes rather than have them 
imposed on the participants by the researcher(s).  
 
5.8 Conclusion 
Being the most common sustained cardiac arrhythmia, AF can carry substantial 
health risk and thus has important public health implications. This was the first study to 
explore AF episodes of illness in terms of the episode length, the number of physician 
visits, the medications prescribed, the referrals made, and the diagnostic investigations 
ordered in general practice.  
 All the findings were statistically significant, with reported large effect sizes. 
Recognizing the limitations of establishing a precise starting point in the episode of AF 
and whether initial symptoms were AF-related, it was on average, between 1.5 and 3 
years and after multiple visits that the majority of patients received a first-time diagnosis 
of AF.  Patients tend to take multiple medications on a regular basis not only for the 
suspected AF but also for other pre-existing comorbidities.  
Further qualitative and mixed methods research can provide an in-depth situated 
knowledge of the patient’s journey by documenting various aspects of their lives 
between physician visits. The contextual approach could allow meaningful interpretation 
of patient history records, physician notes and questionnaires scores. 
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APPENDIX A: List of Atrial Fibrillation-Related ICPC Diagnostic Codes 
ICPC Code ICPC Code Description 
K78 Atrial fibrillation/flutter 
K04 Palpitations/awareness of heart  
K05 Irregular heartbeat other  
R02 Shortness of breath/dyspnea 
A11 Chest pain NOS (not otherwise specified)  
K28 Limited function/disability 
A04 Weakness/tiredness general 
P01 Feeling anxious/nervous/tense 
N17 Vertigo/dizziness  
K77 Heart failure 
K83 Heart valve disease NOS (not otherwise specified) 
K84 Heart disease other 
K29 Cardiovascular symptoms/complications other 
K99 Cardiovascular disease other  
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APPENDIX B: List of Chronic ICPC Diagnostic Codes 
 
    ICPC Code  ICPC Code Description 
A21  Risk factor for malignancy  
A23  Risk factor NOS  
A90  Congenital anomaly nos/multiple  
A93  Premature newborn  
A95  Perinatal mortality  
A96  Death  
B71  Lymphadenitis chronic/non-specific  
B72  Hodgkin's disease/lymphoma  
B73  Leukaemia  
B74  Malignant neoplasm blood other  
B78  Hereditary haemolytic anaemia  
B79  Congenital anomaly blood/lymph other  
B90  HIV infection/AIDS  
D90  Hiatus Hernia  
D92  Diverticular disease  
D93  Irritable bowel syndrome  
D94  Chronic Enteritis/ulcerative colitis  
F74  Neoplasm of eye/adnexa  
F81  Congenital anomaly eye other  
F83  Retinopathy  
F84  Macular degeneration  
F93  Glaucoma  
F94  Blindness  
F95  Strabismus  
H80  Congenital anomaly of ear  
H83  Otosclerosis  
H84  Presbyacusis  
H86  Deafness  
K22  Risk factor for cardiovascular disease  
K73  Congenital anomaly cardiovascular  
K74  Ischaemic heart disease with angina  
K76  Ischaemic heart disease without angina  
K78  Atrial fibrillation/flutter  
K82  Pulmonary heart disease  
K86  Hypertension uncomplicated  
K87  hypertension complicated  
K90  Stroke/cerebrovascular accident  
K91  Cerebrovascular disease  
K92  Atherosclerosis/peripheral vascular disease  
K95  Varicose veins of leg  
K96  Haemorrhoids  
N70  Poliomyelitis  
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N74  Malignant neoplasm nervous system  
N75  Benign neoplasm nervous system  
N76  Neoplasm nervous system unspecified  
N85  Congenital anomaly neurological  
N86  Multiple sclerosis  
N87  Parkinsonism  
N88  Epilepsy  
N89  Migraine  
N94  Peripheral neuritis/neoropathy  
N99  Neurological disease other  
R79  Chronic bronchitis  
R89  Congenital anomaly respiratory  
R95  Chronic obstructive pulmonary disease  
R96  Asthma  
R97  Allergic rhinitis  
S91  Psoriasis  
S97  Chronic  ulcer skin  
T78  Thyroglossal duct/cyst  
T80  Congenital anomaly endocrine/metabolic  
T81  Goitre  
T85  Hyperthyroidism/thyrotoxicosis  
T86  Hypothyroidism/myxoedema  
T89  Diabetes insulin dependent  
T90  Diabetes non-insulin dependent  
T92  Gout  
T93  Lipid disorder  
U85  Congenital anomaly urinary tract  
W13  Sterilization female  
W15  Infertility/subfertility female  
W76  Congenital anomaly complicating pregnancy  
W85  Gestational diabetes  
X11  Menopausal symptom/complaint  
X88  Fibrocystic disease breast  
Y13  Sterilization male  
Y72  Genital herpes male  
Y85  Benign prostatic hypertrophy  
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APPENDIX C: List of Musculoskeletal ICPC Diagnostic Codes 
 
  ICPC Code                      Description  
L01  Neck symptom/complaint  
L04  Chest symptom complaint  
L05  Flank/axilla symptom/complaint  
L07  Jaw symptom/complaint  
L08  Shoulder symptom/complaint  
L09  Arm symptom/complaint  
L10  Elbow symptom/complaint  
L11  Wrist symptom/complaint  
L12  Hand/finger symptom/complaint  
L13  Hip symptom/complaint  
L14  Leg/thigh symptom/complaint  
L15  Knee symptom/complaint  
L16  Ankle symptom/complaint  
L17  Foot/toe symptom/complaint  
L18  Muscle pain  
L19  Muscle symptom/complaint NOS  
L20  Joint symptom/complaint NOS  
L28  Limited function/disability (L)  
L29  Musculoskeletal symptom/complaint other  
L70  Infection of musculoskeletal system  
L71  Malignant neoplasm musculoskeletal  
L72  Fracture: radius/ulna  
L73  Fracture: tibia/fibula  
L74  Fracture: hand/foot bone  
L75  Fracture: femur  
L76  Fracture: other  
L77  Sprain/strain of ankle  
L78  Sprain/strain of knee  
L79  Sprain/strain of joint NOS  
L80  Dislocation/subluxation  
L81  Injury musculoskeletal NOS  
L82  Congenital anomaly musculoskeletal  
L83  Neck syndrome  
L85  Acquired deformity of spine  
L87  Bursitis/tendinitis/synovitis NOS  
L88  Rheumatoid/seropositive arthritis  
L89  Osteoarthrosis of hip  
L90  Osteoarthrosis of knee  
L91  Osteoarthrosis other  
L92  Shoulder syndrome  
L93  Tennis elbow  
L94  Osteochondrosis  
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L95  Osteoporosis  
L96  Acute internal damage knee  
 L97  Neoplasm musculoskeletal benign/unspecified  
 L98  Acquired deformity of limb  
           L99           Musculoskeletal disease other   
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APPENDIX D: List of Psychosocial ICPC Diagnostic Codes 
ICPC Code     Code Description  
Psychological  
P01  Feeling anxious/nervous/tense  
P02  Acute stress reaction  
P03  Feeling depressed  
P04  Feeling/behaving irritable/angry  
P05  Senility, feeling/behaving old  
P06  Sleep disturbance  
P07  Sexual desire reduced  
P08  Sexual fulfillment reduced  
P09  Sexual preference concern  
P10  Stammering/stuttering/tic  
P11  Eating problem in child  
P12  Bedwetting/enuresis  
P13  Encopresis/bowel training problem  
P15  Chronic alcohol abuse  
P16  Acute alcohol abuse  
P17  Tobacco abuse  
P18  Medication abuse  
P19  Drug abuse  
P20  Memory disturbance  
P22  Child behaviour symptom/complaint  
P23  Adolescent behaviour symptom/complaint  
P24  Specific learning problem  
P25  Phase of life problem adult  
P28  Limited function/disability  
P29  Psychological symptom/complaint other  
P70  Dementia  
P71  Organic psychosis other  
P72  Schizophrenia  
P73  Affective psychosis  
P74  Anxiety disorder/anxiety state  
P75  Somatization disorder  
P76  Depressive disorder  
P77  Suicide/suicide attempt  
P78  Neuraesthenia/surmenage  
P79  Phobia/compulsive disorder  
P80  Personality disorder  
P81  Hyperkinetic disorder  
P82  Post-traumatic stress disorder  
P85  Mental retardation  
P86  Anorexia nervosa/bulimia  
P98  Psychosis NOS/other  
P99  Psychological disorders other  
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Fear  
A25  Fear of death/dying  
A26  Fear of cancer NOS  
A27  Fear of other disease NOS  
B25  Fear of AIDS/HIV  
B26  Fear of cancer blood/lymph  
B27  Fear of blood/lymph disease other  
D26  Fear of cancer of digestive system  
D27  Fear of digestive disease other  
F27  Fear of eye disease  
H27  Fear of ear disease  
K24  Fear of heart disease  
K25  Fear of hypertension  
K27  Fear of cardiovascular disease  
L26  Fear of cancer musculoskeletal  
L27  Fear of musculoskeletal disease other  
N26  Fear of cancer of neurological system  
N27  Fear of neurological disease other  
P27  Fear of mental disorder  
R26  Fear of cancer of respiratory system  
R27  Fear of respiratory disease other  
S26  Fear of cancer of skin  
S27  Fear of skin disease other  
T26  Fear of cancer of endocrine system  
T27  Fear of endocrine/metabolic disease other  
U26  Fear of cancer of urinary system  
U27  Fear of urinary disease other  
W02  Fear of pregnancy  
W21  Concern about boday image related to pregnancy  
W27  Fear of complications of pregnancy  
X22  Concern about breast appearance female  
X23  Fear of sexually transmitted disease female  
X24  Fear of sexual dysfunction female  
X25  Fear of genital cancer female  
X26  Fear of breast cancer female  
X27  Fear genital/breast disease female other  
Y24  Fear of sexual dysfunction male  
Y25  Fear of sexually transmitted disease male  
Y26  Fear of genital cancer male  
Y27  Fear of genital disease male other  
Z27  Fear of social problem  
    
Social  
Z01  Poverty/financial problem  
Z02  Food/water problem  
Z03  Housing/neighbourhood problem  
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Z04  Social cultural problem  
Z05  Work problem  
Z06  Unemployment problem  
Z07  Education problem  
Z08  Social welfare problem  
Z09  Legal problem  
Z10  Health care system problem  
Z11  Compliance/being ill problem  
Z12  Relationship problem with partner  
Z13  Partner`s behaviour problem  
Z14  Partner illness problem  
Z15  Loss/death of partner problem  
Z16  Relationship problem with child  
Z18  Illness problem with child  
Z19  Loss/death of child problem  
Z20  Relationship problem parent/family  
Z21  Behaviour problem parent/family  
Z22  Illness problem parent/family  
Z23  Loss/death of parent/family member problem  
Z24  Relationship problem friend  
Z25  Assault/harmful event problem  
Z28  Limited function/disability (Z)  
Z29  
  
Social problem NOS  
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APPENDIX E: Measures of Effect Size  
 
# Measure of 
Effect Size 
Formula Operational Definition Interpretation Applicability 
 
1. 
 
Eta squared 
 
η 2= 
𝑡2
𝑡2+(𝑁1+𝑁2−2)
 
 
Where: 
• η 2 = eta squared 
• t = t-value 
• N1= sample size of 
group 1 
• N2= sample size of 
group 2 
 
Eta squared measures the 
proportion of variance in the 
dependent variable that is 
explained by the independent 
(group) variable 
An eta squared value indicates 
the proportion of the total 
variation in a dependent 
variable Y that is attributed to 
an independent (group) variable 
X. 
 
Eta squared threshold values: 
0 – no association 
0.26 – large effect size 
0.13 – medium effect 
0.02 – small effect 
1 – perfect association 
 
Can be expressed as a 
percentage 
tends to be biased in 
overestimating the 
size of effect in the 
population 
,  
2. 
 
Cohen’s d 
 
 
Cohen's d = (M2 - M1) ⁄ 
SDpooled 
 
Where: 
• M1 = mean value for 
group 1 
• M2 = mean value for 
group 2 
 
Cohen’s d presents the 
difference between the groups 
in terms of standard deviation 
units. 
 
Cohen’s threshold values of 
effect magnitude: 
0.20 – small, but not trivial 
0.50 – medium 
around or above 0.80 – large  
 
If two groups’ means do not 
differ by 0.2 standard 
deviations or more, the 
difference is trivial, despite its 
statistical significance. 
 
appropriate if two 
groups have similar 
standard deviations 
and are of the same 
size; most 
commonly reported 
in medical research 
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• SDpooled = pooled 
standard deviation 
• SD1 = standard 
deviation for group 1 
• SD2 = standard 
deviation for group 2 
 
 
If the value of Cohen’s d is 
larger than 1, the difference 
between the two means is 
larger than one standard 
deviation (large effect). 
 
 
 
3. 
 
Glass’ delta 
 
  = M1 - M2 / SD control  
 
Where: 
•   = Glass’ delta 
• M1 = mean value for 
group 1 
• M2 = mean value for 
group 2 
• SD control = standard 
deviation of the control 
group 
However, Kline180 
recommends reporting 
Glass’ delta twice - 1 and 
2, using the standard 
deviation of each group. 
 
 
Glass’ delta uses the standard 
deviation of the comparison 
group. 
Using the standard deviation of 
the comparison group in the 
denominator is justified when 
the standard deviation of the 
control group is believed to be 
a better estimate of the standard 
deviation in the population to 
which the study results are 
inferred than the standard 
deviation of the experimental 
group is. 
The logic is that the standard 
deviation of the control group 
is not contaminated by the 
treatment effects and, therefore, 
reflects more accurately the 
population standard 
deviation224.  
The difference between the 
groups is presented in terms of 
standard deviation units 
 
If two groups’ means do not 
differ by 0.2 standard 
deviations or more, the 
difference is trivial, despite of 
its statistical significance. 
If the value of Cohen’s d is 
larger than 1, the difference 
between the two means is 
larger than one standard 
deviation 
 
an alternative 
measure for groups 
with substantially 
different standard 
deviations, i. e.., 
with unequal 
variance; also with 
unequal comparison 
group 
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4. 
 
Hedge’s g 
 
 
 
 
Where: 
• g  = Hedge’s g 
• x1 = mean value for 
group 1 
• x2 = mean value for 
group 2 
• n1 = sample size of 
group 1 
• n2 = sample size of 
group 2 
• s1 = standard deviation 
of group 1 
• s2 = standard deviation 
of group 2 
 
 
Hedge’s g provides a measure 
of effect size that is weighted 
according to the relative size of 
each sample. It 
presents the difference between 
the groups in terms of standard 
deviation units. 
 
If two groups’ means do not 
differ by 0.2 standard 
deviations or more, the 
difference is trivial, despite of 
its statistical significance. 
If the value of Hedge’s g is 
larger than 1, the difference 
between the two means is 
larger than one standard 
deviation. 
 
used for unequal or 
small sample sizes  
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 APPENDIX F: Manual Calculation of Effect Size: Eta Squared 
The formula for eta squared is as follows:174 
Eta squared = 
𝑡2
𝑡2+(𝑁1+𝑁2−2)
 
Replacing with the appropriate values for each of the five dependent variables:  
1) Eta squared (the number of physician visits as a dependent variable) = 
=
32.6822
32.6822+(1487+1287−2)
 = 
1068.113124
1068.113124+2772
 = 
1068.113124
 3840.113124
 = 0.2781462654 
 
             Eta squared = 0.28 
 
2) Eta squared (the number of different medication names as a dependent variable) = 
=
19.1092
19.1092+(1845+1327−2)
 = 
365.153881
3535.153881
  = 0.1032922168 
 
Eta squared = 0.10 
 
 
3) Eta squared (the episode length as a dependent variable) = 
=
20.2312
20.2312+(361+1327−2)
 = 
409.293361
2095.293361
  = 0.1953394062 
 
Eta squared = 0.20 
 
 
4) Eta squared (the number of diagnostic investigations as a dependent variable) = 
=
4.9192
4.9192+(168+1327−2)
 = 
24.196561
1517.196561
 = 0.0159482045 
 
Eta squared = 0.02 
 
Ever,  
5) Eta squared (the number of referrals as a dependent variable) = 
=
4.9002
4.9002+(106+1327−2)
 = 
24.01
1455.01
 =  0.0165016048 
 
Eta squared = 0.02 
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APPENDIX G: Semi-Manual Calculation of Effect Size: Eta Squared 
IBM SPSS does not provide effect size statistics for t-tests in the output174. However, it is 
possible to get an eta value through crosstabs in descriptive statistics. Below are the IBM 
SPSS outputs with eta values for the five dependent variables. 
1) Eta (the number of physician visits as a dependent variable) = 0.516 
 
 
2) Eta (the number of different medication names as a dependent variable) = 0.311 
 
 
 
3) Eta (the episode length as a dependent variable) = 0.468 
 
 
4) Eta (the number of diagnostic investigations as a dependent variable) = 0.133 
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5) Eta (the number of referrals as a dependent variable) = 0.037 
 
 
From the eta values above, we can manually calculate eta squared values for each 
of the five dependent variables: 
1) Eta squared (the number of physician visits as a dependent variable) = 0.5162 = 
0.266256 = 0.27 
2) Eta squared (the number of different medication names as a dependent variable) = 
0.3112 = 0.096721 = 0.10 
3) Eta squared (the episode length as a dependent variable) = 0.4682 = 0.219024 = 0.22 
4) Eta squared (the number of diagnostic investigations as a dependent variable) = 0.1332 = 
0.017689 = 0.02 
5) Eta squared (the number of referrals as a dependent variable) = 0.0372= 0.001369 = 0.001 
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APPENDIX H: Summary Table of Eta Squared Values 
 
# Dependent variable SPSS 
Calculated Eta 
Value 
Manually 
Calculated Eta 
Value 
Magnitude of 
Effect 
1. The number of physician 
visits 
 
0.266256 
(0.27) 
0.2781462654 
(0.28) 
large  
2. The number of different 
medication names 
 
0.096721 
(0.10) 
0.1032922168 
(0.10) 
small 
3. The episode length 0.219024 
(0.22) 
 
0.1953394062 
(0.20) 
medium 
4. The number of diagnostic 
investigations 
 
0.017689 
(0.02) 
0.0159482045 
(0.02) 
small 
5. The number of referrals 
 
 
0.001369 
(0.001) 
0.0165016048 
(0.02) 
almost no effect 
 
NOTES: 
1Eta squared ranges from 0 to 1174, 0 meaning “no association” and 1 representing “perfect 
association”. 
2Eta squared measures the proportion of variation in a dependent variable that is related to 
the membership of different groups defined by an independent variable (or a group 
variable). 
3Eta squared assesses how much variation in the dependent variable is explained by 
variation of the independent variable. 
4 The variance can be expressed as percentage by multiplying an eta squared value by 100. 
5Interpretation scheme: 
0 – no association 
0.02 – small effect size 
0.13 – medium effect size 
0.26 – large effect size 
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1 – perfect association 
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APPENDIX I: Calculation of Cohen’s d 
 
Using the information provided in the IBM SPSS output for the independent-samples t-
test, i. e., mean and standard deviation values for both groups, and with the help of an 
online calculator from https://www.socscistatistics.com/effectsize/Default3.aspx, we 
calculated Cohen’s d for the five dependent variables. 
 
The formula for Cohen’s d is as follows: 
 
Cohen's d = (M2 - M1) ⁄ SDpooled 
 
Where: 
• M1 = mean value for group 1 
• M2 = mean value for group 2 
• SPpooled = pooled standard deviation 
• SD1 = standard deviation for group 1 
• SD1 = standard deviation for group 2 
 
1) Cohen’s d (the number of physician visits as a dependent variable) = (13.5835 - 
33.1742) ⁄ 15.987918 = 1.225344. 
 
2) Cohen’s d (the number of different medication names as a dependent variable) = 
(13.2683 - 21.1301) ⁄ 11.636642 = 0.675607. 
 
3) Cohen’s d (the episode length as a dependent variable) = (560.17 – 1019.27)/369.207639 
= 1.243474. 
 
4) Cohen’s d (the number of diagnostic investigations as a dependent variable) = (3.2781 - 
4.875) ⁄ 3.858248 = 0.413893. 
 
5) Cohen’s d (the number of referrals as a dependent variable) = (0.7769 - 
1.2347) ⁄ 1.293155 = 0.354018. 
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NOTES: 
1Cohen’s d presents the difference between the groups in terms of standard deviation units. 
2A negative sign before the value is uninformative of the effect size. The negative sign indicates 
that there is a mean increase from one group to the other. 
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APPENDIX J: Calculation of Hedge’s g 
 
Using the information provided in the IBM SPSS output for the independent-samples t-test, i. e., 
mean and standard deviation values for both groups, and with the help of an online calculator 
from https://www.socscistatistics.com/effectsize/Default3.aspx, we calculated Hedge’s g for the 
five dependent variables: 
 
The formula for Hedge’s g is as follows: 
 
 
Where: 
• g  = Hedge’s g 
• x1 = mean value for group 1 
• x2 = mean value for group 2 
• n1 = sample size of group 1 
• n2 = sample size of group 2 
• s1 = standard deviation of group 1 
• s2 = standard deviation of group 2 
 
1) Hedge’s g (the number of physician visits as a dependent variable) = (13.5835 - 
33.1742) ⁄ 16.227598 = 1.207246. 
2) Hedge’s g (the number of different medication names as a dependent variable) = (13.2683 - 
21.1301) ⁄ 11.839563 = 0.664028. 
3) Hedge’s g (the episode length as a dependent variable) = (560.17 – 1019.27)/355.628446 = 
1.290954. 
4) Hedge’s g (the number of diagnostic investigations as a dependent variable) = (3.2781 - 
4.875) ⁄ 3.749238 = 0.425927. 
5) Hedge’s g (the number of referrals as a dependent variable) = (0.7769 - 1.2347) ⁄ 1.609812 = 
0.284381. 
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NOTES: 
1Hedge’s g provides a measure of effect size that is weighted according to the relative size of 
each sample. 
2Hedge’s g presents the difference between the groups in terms of standard deviation units. 
3Hedge’s g used for unequal or small sample sizes. 
  4Hedge’s g results are deemed most valid as the AF and comparison groups have different 
sample sizes. 
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APPENDIX K: Representativeness of DELPHI Population 
 
Prevalence of Atrial Fibrillation by Age Group 
Age 
(years) 
  
Number of 
Patients  
  
Number of 
patients  with 
atrial 
fibrillation 
Percentage of 
patients with 
atrial 
fibrillation  
0-9 3510 * * 
10-19 3878 8 0.2% 
20-29 5669 33 0.6% 
30-39 5468 33 0.6% 
40-49 5477 55 1.0% 
50-59 7608 129 1.7% 
60-69 7190 250 3.5% 
70-79 5062 402 7.9% 
80-89 2970 425 14.3% 
90-99 1171 157 13.4% 
100+ 93 6 6.5% 
Total 48096 1500 3.1% 
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APPENDIX K: Representativeness of DELPHI Population Continued 
 
Age and sex distribution of patients with atrial fibrillation 
Gender 
 
  
Number of 
Patients   
Mean 
Age 
  
Standard 
Deviation 
  
Range 
 
  
95% C.I. 
Male 800 73.2 14.9 10-107 72.2 -74.2 
Female 700 72.1 17.8 2-104 70.8-73.4 
Total 1500 72.6 16.4 2-107 71.8-73.4 
 
 
Gender 
 
  
Frequency 
 
  
Percent 
 
  
Valid 
Percent 
Cumulative 
Percent 
  
Male 800 53.3 53.3 53.3 
Female 700 46.7 46.7 100.0 
Total 1500 100.0 100.0  
 
 
Mode of Patient 
Identification 
  
Number 
of 
Patients  
Percentage 
of Patients 
(%)  
95% C.I. 
 
  
Continuous Patient 
Profile 424 28.3 26.0-30.6 
ICD9 code 427x 696 46.4 43.9-49.0 
Both CPP and ICD9 380 25.3 23.1-27.6 
Total 1500 100  
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APPENDIX L: Age and Sex Distribution in the ICPC-Coded DELPHI Population  
(N=3,525) and the 2016 Canadian Census Population (N= 35,151,728) 
 
   
Median 
Age  
(years)  
Median 
age Males  
(years)  
Median age  
Females  
(years)  
% Males 
  
 
% Females 
 
  
Census 
Population  40  39   41  49%  51%  
ICPC  
Population  54       53 56  44%  56%  
  
NOTES:  
N=3,525 - the sample of ICPC-coded patients coded from the Deliver Primary Health Care 
Information (DELPHI) Project. 
N=35,151,728 - the 2016 Canadian Census data from Statistics Canada219.  
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